[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3180
1. Gawkowska-Suwinska M, Fijałkowski M, Białas B, Szlag M, Kellas-Ślęczka S, Nowicka E, Behrendt K, Plewicki G, Smolska-Ciszewska B, Giglok M, Zajusz A, Owczarek G: Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy. J Contemp Brachytherapy; 2009 Dec;1(4):211-215
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy.
  • PURPOSE: The aim of the study was to analyze early effects and toxicity of salvage high dose rate brachytherapy for local recurrences of adenocarcinoma of the prostate after external beam radiotherapy (EBRT).
  • MATERIAL AND METHODS: In MCS Memorial Institute of Oncology in Gliwice a research programme on salvage HDR brachytherapy for local recurrences of prostate cancer treated previously with EBRT has been ongoing since February 2008.
  • CONCLUSIONS: Salvage brachytherapy for localized prostate cancer (3 × 10 Gy every 14 days) seems to be a safe and well tolerated procedure.
  • A significant decline in prostate-specific antigen (PSA) level is seen in patients with hormone-responsive cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28050174.001).
  • [ISSN] 1689-832X
  • [Journal-full-title] Journal of contemporary brachytherapy
  • [ISO-abbreviation] J Contemp Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; prostate cancer / radiotherapy / recurrences / salvage brachytherapy
  •  go-up   go-down


2. Raina K, Rajamanickam S, Singh RP, Agarwal R: Chemopreventive efficacy of inositol hexaphosphate against prostate tumor growth and progression in TRAMP mice. Clin Cancer Res; 2008 May 15;14(10):3177-84
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemopreventive efficacy of inositol hexaphosphate against prostate tumor growth and progression in TRAMP mice.
  • PURPOSE: Herein, for the first time, we evaluated the in vivo chemopreventive efficacy of inositol hexaphosphate (IP6), a major constituent of high-fiber diets, against prostate tumor growth and progression in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
  • Prostate tissue was subjected to histopathologic analysis and to immunohistochemical analyses for proliferation and apoptosis.
  • IP6 inhibited prostate cancer progression at prostatic intraepithelial neoplasia stage and strongly reduced the incidence of adenocarcinoma (prostatic intraepithelial neoplasia/adenocarcinoma, 75:25% in the IP6 group versus 39:61% in the control group; P < 0.05).
  • Immunohistochemical analysis of prostate tissue showed a 26% decrease (P < 0.05) in proliferation cell nuclear antigen-positive cells and a 3.5-fold increase in apoptotic cells with no effect on Tag expression by IP6.
  • CONCLUSIONS: These findings are both novel and highly significant in establishing for the first time that oral IP6, without any toxicity, suppresses prostate tumor growth and progression at the neoplastic stage, thereby reducing the incidence of adenocarcinoma through its antiproliferative and proapoptotic effects, and thus indicating that IP6 could have potential chemopreventive effects against human prostate cancer.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr. 2003 Nov;133(11 Suppl 1):3778S-3784S [14608114.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3855-61 [14666688.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):244-50 [14734476.001]
  • [Cites] Carcinogenesis. 1988 Apr;9(4):577-80 [2833366.001]
  • [Cites] Carcinogenesis. 1989 Mar;10(3):625-6 [2924408.001]
  • [Cites] Carcinogenesis. 1989 Aug;10(8):1461-3 [2752519.001]
  • [Cites] Free Radic Biol Med. 1990;8(1):61-9 [2182395.001]
  • [Cites] Cancer Lett. 1992 Jul 10;64(3):195-202 [1638512.001]
  • [Cites] Cancer Lett. 1992 Jul 31;65(1):9-13 [1511413.001]
  • [Cites] Mol Endocrinol. 1994 Feb;8(2):230-9 [8170479.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Carcinogenesis. 1995 Aug;16(8):1975-9 [7634429.001]
  • [Cites] Toxicol Pathol. 1996 Jul-Aug;24(4):502-4 [8864193.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2873-8 [9230193.001]
  • [Cites] Life Sci. 1997;61(4):343-54 [9244360.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):152-7 [15598953.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):573-80 [15965492.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):2891-903 [16080543.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2005 Nov;5(6):603-12 [16305482.001]
  • [Cites] Annu Rev Med. 2006;57:49-63 [16409136.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):751-78 [16954429.001]
  • [Cites] Nutr Cancer. 2006;55(2):109-25 [17044765.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5976-82 [17575168.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):11083-91 [18006855.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3A):1377-84 [9673344.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3A):1479-84 [9673359.001]
  • [Cites] Annu Rev Nutr. 1998;18:413-40 [9706231.001]
  • [Cites] Anticancer Res. 1998 Nov-Dec;18(6A):4083-90 [9891449.001]
  • [Cites] Anticancer Res. 1998 Nov-Dec;18(6A):4091-6 [9891450.001]
  • [Cites] Neoplasia. 2004 Sep-Oct;6(5):646-59 [15548374.001]
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5A):3659-61 [10625934.001]
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5A):3671-4 [10625937.001]
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5A):3749-52 [10625952.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1051-9 [11007941.001]
  • [Cites] Carcinogenesis. 2000 Dec;21(12):2225-35 [11133812.001]
  • [Cites] Biofactors. 2000;12(1-4):45-51 [11216504.001]
  • [Cites] Drugs Exp Clin Res. 2001;27(1):17-26 [11276826.001]
  • [Cites] IARC Sci Publ. 2002;156:387-9 [12484214.001]
  • [Cites] Complement Ther Med. 2002 Dec;10(4):229-34 [12594974.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):555-63 [12663518.001]
  • [Cites] Urol Clin North Am. 2003 May;30(2):209-17 [12735498.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):933-9 [14504208.001]
  • [Cites] Int J Oncol. 2003 Nov;23(5):1413-8 [14532984.001]
  • (PMID = 18483386.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA116636-02; United States / NCI NIH HHS / CA / R01 CA116636; United States / NCI NIH HHS / CA / R01 CA116636-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7IGF0S7R8I / Phytic Acid
  • [Other-IDs] NLM/ NIHMS206144; NLM/ PMC3049549
  •  go-up   go-down


3. Barbón JJ, González-Tuero J, Gay LL, Pérez-García FJ, Sampedro A: [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy]. Arch Soc Esp Oftalmol; 2007 Nov;82(11):715-7
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy].
  • [Transliterated title] Regresión de una metástasis coroidea de adenocarcinoma de próstata con tratamiento hormonal.
  • CASE REPORT: We report a case of a patient diagnosed with prostatic adenocarcinoma with multiple bone metastases and a choroidal metastasis in his left eye.
  • DISCUSSION: Complete resolution of choroidal metastases of prostatic adenocarcinoma with hormonal therapy is exceptional, but the effect of this treatment on such metastases should be observed before recommending radiation therapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Androgen Antagonists / therapeutic use. Anilides / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Choroid Neoplasms / secondary. Nitriles / therapeutic use. Prostatic Neoplasms / drug therapy. Tosyl Compounds / therapeutic use
  • [MeSH-minor] Aged. Biopsy. Bone Neoplasms / secondary. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Prostate / pathology. Prostate-Specific Antigen / blood. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979041.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Tosyl Compounds; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


Advertisement
4. Mohamed MA, Greif PA, Diamond J, Sharaf O, Maxwell P, Montironi R, Young RA, Hamilton PW: Epigenetic events, remodelling enzymes and their relationship to chromatin organization in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. BJU Int; 2007 Apr;99(4):908-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic events, remodelling enzymes and their relationship to chromatin organization in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.
  • OBJECTIVE: To explore the nuclear chromatin phenotype, overall epigenetic mechanisms, chromatin remodelling enzymes and their role as diagnostic biomarkers in prostate lesions, using high-resolution computerized quantitative digital image analysis (DIA).
  • MATERIALS AND METHODS: A tissue microarray (TMA) was constructed using paraffin wax-embedded prostatic tissues from 78 patients, containing 30 cores of benign prostatic hyperplasia (BPH), 10 of low-grade prostatic intraepithelial neoplasia (LGPIN), 38 of prostate adenocarcinoma, 20 of BPH tissue excised at 0.6-1 mm from LGPIN lesions, and 10 of BPH prostatic tissues obtained 0.6-1 mm from high-grade PIN (HGPIN) lesions.
  • In PIN lesions, there was a high chromatin content with DNA-hypermethylation, while in prostatic adenocarcinoma there was a lower chromatin content with DNA-hypomethylation and H3K9-hypoacetylation.
  • CONCLUSIONS: The present study confirms the ability of high-resolution computerized digital imaging of nuclear texture features to detect changes in chromatin phenotype, epigenetic events and the presence of chromatin remodelling, factors that can be used to distinguish between different prostatic pathologies, i.e.
  • BPH, LGPIN, HGPIN and prostate adenocarcinoma, and further allow the detection of MAC near PIN lesions.
  • Further studies are needed to elucidate the complex interplay between chromatin structure, its modifications and the progression of prostate cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Chromatin. Prostatic Intraepithelial Neoplasia / genetics. Prostatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378849.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromatin
  •  go-up   go-down


5. Martina MS, Wilhelm C, Lesieur S: The effect of magnetic targeting on the uptake of magnetic-fluid-loaded liposomes by human prostatic adenocarcinoma cells. Biomaterials; 2008 Oct;29(30):4137-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of magnetic targeting on the uptake of magnetic-fluid-loaded liposomes by human prostatic adenocarcinoma cells.
  • Interactions of magnetic-fluid-loaded liposomes (MFL) with human adenocarcinoma prostatic cell line PC3 were investigated in vitro.
  • [MeSH-major] Adenocarcinoma / metabolism. Drug Delivery Systems / methods. Liposomes / chemistry. Liposomes / pharmacokinetics. Magnetics. Prostatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18667235.001).
  • [ISSN] 0142-9612
  • [Journal-full-title] Biomaterials
  • [ISO-abbreviation] Biomaterials
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Liposomes
  •  go-up   go-down


6. Cho NY, Choi M, Kim BH, Cho YM, Moon KC, Kang GH: BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer; 2006 Oct 15;119(8):1858-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRAF and KRAS mutations in prostatic adenocarcinoma.
  • RAS mutations are known to occur in prostate adenocarcinomas, but little is known about BRAF mutations in these tumors.
  • In the present study, BRAF and KRAS mutations were characterized in 206 prostate adenocarcinomas by enhanced PCR-RFLP and direct sequencing.
  • Mutations in codon 600 of BRAF were identified in 21 (10.2%) of 206 prostate adenocarcinomas.
  • KRAS mutations in codons 12 or 13 were found in 15 (7.3%) of 206 prostate adenocarcinomas.
  • Prostate adenocarcinomas with a BRAF mutation tended to show higher preoperative serum PSA levels, Gleason scores and tumor stages than prostate adenocarcinomas with a KRAS mutation.
  • The results obtained show that BRAF mutations are as uncommon as KRAS mutations in prostate adenocarcinoma.
  • Although BRAF and KRAS are members of the same RAS/ERK signaling pathway, prostate adenocarcinomas with a BRAF mutation showed clinicopathologic features that differed from those of prostate adenocarcinoma with a KRAS mutation.
  • [MeSH-major] Adenocarcinoma / genetics. Oncogene Protein p21(ras) / genetics. Prostatic Neoplasms / genetics. Proto-Oncogene Proteins B-raf / genetics


7. Bensalah K, Fleureau J, Rolland D, Rioux-Leclercq N, Senhadji L, Lavastre O, Guillé F, Patard JJ, de Crevoisier R: [Optical spectroscopy: a new approach to assess urological tumors]. Prog Urol; 2010 Jul;20(7):477-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La spectroscopie optique : une nouvelle approche pour l'étude des tumeurs urologiques.
  • Several publications specifically aimed at assessing prostate cancers, renal carcinomas and urothelial tumors.
  • Optical spectroscopy can differentiate benign (adenoma or inflammation) and malignant (adenocarcinoma) prostatic tissues.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20656268.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] France
  •  go-up   go-down


8. Wan Muhaizan WM, Ahmad PK, Phang KS, Arni T: p53 and p21/WAF-1 overexpressions in prostatic adenocarcinoma. Malays J Pathol; 2006 Dec;28(2):93-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 and p21/WAF-1 overexpressions in prostatic adenocarcinoma.
  • OBJECTIVES: This study was carried out to determine the role of p53 and p21 in the pathogenesis of prostatic adenocarcinoma and their association with tumour grade.
  • METHOD: Sixty-seven histologically confirmed prostatic adenocarcinoma cases collected from Hospital Universiti Kebangsaan Malaysia and General Hospital Kuala Lumpur were studied.
  • RESULTS: IHC positivity for p53 was expressed in 1/2 (50%) low grade, 14/33 (42%) intermediate grade, and 21/32 (66%) high grade tumours. p21 was expressed in 0/2 low grade, 16/33 (48%) intermediate grade and 15/32 (47%) high grade tumours. p53 and p21 expressions did not show statistically significant correlation with the different grades of prostatic adenocarcinoma or with each other (p = 0.42).
  • CONCLUSION: Although the p53 positivity rate was higher in high-grade prostate adenocarcinoma, this was not statistically significant.
  • [MeSH-major] Adenocarcinoma / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Prostatic Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376798.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


9. San Miguel Fraile P, Dos Santos JE, Pélaez Boismorand E, Ortiz Rey JA, Iglesias Rodríguez B, Cambronero Santos J, Fajardo Seijo JL, Rodríguez Costas JM, Fernández Regueiro M: [Expression of the cerbB-2 (HER-2/neu) oncoprotein in prostatic adenocarcinoma]. Actas Urol Esp; 2005 Jan;29(1):64-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of the cerbB-2 (HER-2/neu) oncoprotein in prostatic adenocarcinoma].
  • [Transliterated title] Estudio de la expresión de cerbB-2 en el adenocarcinoma de próstata.
  • OBJECTIVES: Our aim is to determine the expression of the cerbB-2 oncoprotein in prostate cancers using an immunohistochemistry staining and to compare these results with several clinical and histological prognostic factors.
  • METHODS: An immunohistochemical staining using the cerbB-2 monoclonal antibody (Dako) was performed in 32 radical prostatectomy specimens diagnosed of adenocarcinoma.
  • 1) This study shows that 44% of all prostate cancer express the cerbB-2 oncoprotein with immunohistochemical technique.
  • 2) These findings suggest that is necessary to standardize the immunohistochemical staining procedure with cerbB-2 in prostate adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Prostatic Neoplasms / metabolism. Receptor, ErbB-2 / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15786765.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


10. Guzman Martinez-Valls PL, Rodríguez Tardido A, Honrubia Vilchez B, Izquierdo Morejon E, Pietricica BN, Montoya Chinchilla R, Rosino Sanchez A, Hita Villaplana G, Romero Hoyuela A, Miñana Lopez B: [Frontal mass simulating lipoma as a clinical presentation of prostatic adenocarcinoma]. Arch Esp Urol; 2009 Jan-Feb;62(1):66-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Frontal mass simulating lipoma as a clinical presentation of prostatic adenocarcinoma].
  • [Transliterated title] Bultoma frontal simulando lipoma como manifestación de adenocarcinoma de próstata.
  • OBJECTIVE: To report one case of metastatic prostatic carcinoma with a gaudy presentation as a lump which resulted to be a cutaneous metastasis.
  • METHODS: We describe the debut in a patient, who thanks to the pathologic analysis of a lesion mimicking a lipoma, which was reported as adenocarcinoma, was worked up for prostatic adenocarcinoma and diagnosis was reached.
  • We performed a bibliographic review using an electronic bibliographic search in PubMed (MEDLINE) using the terms "Prostatic Neoplasm" (MesH) AND "Neoplasm Metastasis" (MesH) AND "cutaneous" (free text).
  • Cutaneous metastasis of prostatic origin appear in less than 0.3% of the cases, because bone, lymph node, and visceral disease are more frequent.
  • CONCLUSIONS: Cutaneous metastases of prostatic adenocarcinoma are very rare, but even rarer is it being the debut of the disease.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / secondary. Lipoma / diagnosis. Prostatic Neoplasms / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / secondary
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male


11. Chuang AY, Epstein JI: Xanthoma of the prostate: a mimicker of high-grade prostate adenocarcinoma. Am J Surg Pathol; 2007 Aug;31(8):1225-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Xanthoma of the prostate: a mimicker of high-grade prostate adenocarcinoma.
  • Prostatic xanthoma may mimic high-grade prostatic adenocarcinoma or prostate cancer treated with hormone therapy.
  • From 1995 to 2006, 40 cases of prostatic xanthoma were diagnosed at The Johns Hopkins Hospital.
  • Xanthoma was found on needle biopsy in 25 cases, with 2 cases noted on transurethral resection of prostate.
  • Twenty-six cases contained only 1 focus of prostatic xanthoma with 1 case having 3 foci on the same core biopsy specimen.
  • Ten xanthomas consisted of cords and individual cells infiltrating the prostatic stroma, further mimicking high-grade prostate carcinoma.
  • One of 15 (6.7%), 2/17 (11.8%), and 1/12 (8.3%) cases were positive for prostate-specific antigen, prostate-specific acid phosphatase, and alpha-methylacyl-CoA racemase, respectively.
  • Careful attention to morphology with adjunctive use of CD68 and CAM5.2 immunohistochemical stains are helpful in the diagnosis of prostatic xanthoma, especially in difficult cases with an infiltrative pattern.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Neoplasms / pathology. Xanthomatosis / pathology
  • [MeSH-minor] Biomarkers / metabolism. Biopsy, Needle. Diagnosis, Differential. Humans. Immunoenzyme Techniques. Male

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667547.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


12. Winkfield KM, Chen M, Dosoretz DE, Salenius SA, Katin MJ, Ross R, D'Amico AV: Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate. J Clin Oncol; 2009 May 20;27(15_suppl):5068

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate.
  • : 5068 Purpose: We investigated whether race was associated with risk of death following brachytherapy-based treatment for localized prostate cancer.
  • METHODS: The study cohort was comprised of 4,880 men with clinical stage T1-3N0M0 prostate cancer and minimum follow-up of 2 years who underwent brachytherapy-based treatment at 20 centers within the 21st Century Oncology consortium.
  • CONCLUSIONS: African-American and Hispanic race as compared to white race appear to confer a higher risk of mortality following brachytherapy-based treatment in men with localized or locally advanced prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964249.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Sonpavde G, Frolov A, Macdonell V, Hayes TG, Mims MP, Ayala GE, Wheeler TM, Thompson TC, Ittman MM, Kadmon D: Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer (PCa) followed by radical prostatectomy (RP). J Clin Oncol; 2009 May 20;27(15_suppl):5127

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer (PCa) followed by radical prostatectomy (RP).
  • Histological evidence of adenocarcinoma of the prostate was required with clinical stage T<sub>1c</sub> or T<sub>2a</sub> with Gleason 8-10 disease, or clinical stage T<sub>2b</sub>-T<sub>2c</sub> with Gleason grade 7 and PSA of >10 ng/mL, or clinical stage T<sub>3</sub>.
  • Upregulation of apoptosis, proliferation and phosphorylated (p)-Akt have been previously reported in a subset of patients by our group (Ayala GE et al, Clin Cancer Res. 2008;14:7511-8).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964403.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Renzulli JF 2nd, Dooner G, Owens C, Colvin G, Dooner M, Del Tatto M, Goldstein L, Quesenberry P: Microvesicular-mediated gene transfer of prostate tumor markers. J Clin Oncol; 2009 May 20;27(15_suppl):e16076

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microvesicular-mediated gene transfer of prostate tumor markers.
  • Recent work has focused on the potential for cancer vaccines via microvesicles.
  • Our objective is to determine whether there is transfer of genetic or transcriptional factors via microvesicles from human prostate cancer cells to fresh human marrow cells.
  • METHODS: Fresh prostate tissue was harvested from surgical specimens following radical retropubic prostatectomy.
  • Samples were histologically confirmed to contain prostatic adenocarcinoma.
  • Co-cultures were established using a transwell system in which 0.05-0.100 grams of prostate tissue was minced and co-cultured with 1-3 million normal, human donor marrow cells for 2-7 days.
  • Target cells were collected and total RNA was analyzed for prostate-specific gene expression byReal Time RT-PCR.
  • RESULTS: We have observed significant increases in gene expression in marrow cells co-cultured with prostate tumor cells (Gleason grades 6-9).
  • CONCLUSIONS: These studies demonstrate that prostate specific genes are present in fresh human marrow cells after co-culture with tumor tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963050.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Luu T, Sartor O, Dandade N, Halabi S, Bennett C: Comparability of health-related quality of life (HRQOL), treatment decision making, and treatment satisfaction after PSA recurrence among prostate cancer patients who receive hormone therapy (HT) versus observation (OBS): Results from the COMPARE registry. J Clin Oncol; 2009 May 20;27(15_suppl):5131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparability of health-related quality of life (HRQOL), treatment decision making, and treatment satisfaction after PSA recurrence among prostate cancer patients who receive hormone therapy (HT) versus observation (OBS): Results from the COMPARE registry.
  • METHODS: The Comprehensive Multicenter Prostate Adenocarcinoma Registry (COMPARE) is an observational registry of men with PSA failure.
  • The median time between cancer diagnosis and registry enrollment was 6 years.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964431.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Lujan M, Cardona AF, Yepes A, Carrasco-Chaumel E, Reveiz L, Otero JM: Myelophthisis in solid tumors: Old aspects, new concepts (ONCOLGroup study). J Clin Oncol; 2009 May 20;27(15_suppl):e20672

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-seven pts (30%) had breast cancer, pathology followed by primary unknown tumours (21%), rabdomiosarcoma (10%), prostate adenocarcinoma (10%), gastric carcinoma (7%) and others (22%).
  • Forty-three pts received chemotherapy following the diagnosis of medullar infiltration, and normal leukocyte count was being seen in 40% of them after such treatment.
  • Nine episodes of febrile neutropenia were found; median overall survival (OS) following the diagnosis of neoplasia and myelophtisis were 13.8 months and 2.2 months respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961689.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Capdevila Querol S, Jurado Troyano I, Lamas Moure S, Aguilar Ruiz A, Alcoberro Turu A, Bernal Dzekonski G: [Embryonal rhabdomyosarcoma of spermatic cord and prostatic adenocarcinoma. Case report and review of the literature]. Actas Urol Esp; 2008 Oct;32(9):945-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Embryonal rhabdomyosarcoma of spermatic cord and prostatic adenocarcinoma. Case report and review of the literature].
  • [Transliterated title] Rabdomiosarcoma embrionario del cordón espermático asociado a adenocarcinoma prostatico. Presentación de un caso y revisión de la literatura.
  • The histology (rhabdomyosarcoma), the age of the patient and its association with a prostatic adenocarcinoma has developed this case report.
  • [MeSH-major] Adenocarcinoma. Genital Neoplasms, Male. Prostatic Neoplasms. Rhabdomyosarcoma. Spermatic Cord

  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19044307.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 8
  •  go-up   go-down


18. Bauduceau O, Vedrine L, Chargari C, Ceccaldi B, Le Moulec S, Houlgatte A: [Testicular metastasis of prostatic adenocarcinoma: a case report]. Prog Urol; 2007 Apr;17(2):251-2
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular metastasis of prostatic adenocarcinoma: a case report].
  • Metastasis of prostate adenocarcinoma to testis is an extremely rare occurrence.
  • Orchiectomy is necessary to confirm histopathological diagnosis.
  • Metastatic carcinoma of the prostate to the testis is a commonly accepted as a sign of disseminated disease.
  • We report a case of a 62-year-old patient who presented a prostatic carcinoma with a testicular metastasis.
  • [MeSH-major] Adenocarcinoma / secondary. Prostatic Neoplasms / pathology. Testicular Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17489329.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


19. Barbosa PF, Malafaia O, Ribas-Filho JM, Czeczko NG, Ribas CM, Cuenca RM, Chula DC: [Cytophotometric expression of tumor antigen markers Ki-67 and CD-34 in prostate adenocarcinoma]. Rev Col Bras Cir; 2009 Dec;36(6):498-503
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytophotometric expression of tumor antigen markers Ki-67 and CD-34 in prostate adenocarcinoma].
  • [Transliterated title] Estudo citofotométrico da expressão dos marcadores tumorais Ki-67 e CD34 no adenocarcinoma de próstata.
  • OBJECTIVE: To quantify the percentage of immunostaining through the labeling index as well as the optical density of Ki-67 and CD34 in prostate adenocarcinoma and compare the results between markers.
  • METHODS: Markers Ki-67 and CD34 were studied using immunohistochemistry in 34 cases of prostate adenocarcinoma from radical prostatectomies performed at the Hospital Regional do Gama in Brasilia, Brazil from 2000 through 2005.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, CD34 / metabolism. Biomarkers, Tumor / metabolism. Ki-67 Antigen / metabolism. Prostatic Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20140393.001).
  • [ISSN] 1809-4546
  • [Journal-full-title] Revista do Colégio Brasileiro de Cirurgiões
  • [ISO-abbreviation] Rev Col Bras Cir
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


20. Llarena Ibarguren R, García-Olaverri Rodríguez J, Villafruela Mateos A, Azurmendi Arin I, Olano Grasa I, Pertusa Peña C: [Metastases in the paranasal sinuses secondary to prostatic adenocarcinoma]. Arch Esp Urol; 2007 Nov;60(9):1.137-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastases in the paranasal sinuses secondary to prostatic adenocarcinoma].
  • [Transliterated title] Metástasis en senos paranasales secundaria a adenocarcinoma prostático.
  • OBJECTIVE: To report a new case of exceptional metastases from a prostatic carcinoma.
  • METHODS: 64-year-old male with nine months history of disseminated prostate cancer, taking hormonal treatment and biphosphonates, who presents with rising PSA, facial dysesthesia and left exophtalmos.
  • RESULTS: Once the diagnosis was established hormonal maneuvers were performed and chemotherapy with docetaxel was administered achieving at the start of treatment measurable disease stabilization with biochemical remission of PSA levels, followed posteriorly by progression without changes in the metastatic images.
  • CONCLUSIONS: 1% of the prostatic tumors involve the head in their evolution.
  • [MeSH-major] Adenocarcinoma / secondary. Paranasal Sinus Neoplasms / secondary. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18077874.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


21. Ahmadi SA, Moinfar M, Gohari Moghaddam K, Bahadori M: Practical application of angiogenesis and vasculogenic mimicry in prostatic adenocarcinoma. Arch Iran Med; 2010 Nov;13(6):498-503
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practical application of angiogenesis and vasculogenic mimicry in prostatic adenocarcinoma.
  • Although the association between vasculogenic mimicry and poor prognosis has been established in some tumors, there are only a few studies concerning prostatic carcinoma.
  • METHODS: Using a histochemical and immunohistochemical dual staining method for PAS-CD34 and special immunohistochemical staining for laminin, we studied the presence and pattern of non-endothelialized channels known as vasculogenic mimicry as well as the quantity of endothelialized vessels designated as microvessel density in usual paraffin sections of 20 low-grade and 20 high-grade prostatic adenocarcinomas by routine light microscopy.
  • CONCLUSION: Unlike other cancers and despite the results of in vitro studies on prostatic adenocarcinoma, we were not able to demonstrate a significant relationship between vasculogenic mimicry channels and histologic grading as one of the most important prognostic factors; however, this may be due to an inherent limitation of prostatic tissue imposed by abundant smooth muscle fibers stained by this method.
  • On the other hand, microvessel density scoring appears to be an important, simple, and applicable histologic tool for prostatic cancer evaluation in daily practice.
  • [MeSH-major] Adenocarcinoma / blood supply. Neovascularization, Pathologic / pathology. Prostatic Neoplasms / blood supply

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21039005.001).
  • [ISSN] 1735-3947
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34
  •  go-up   go-down


22. Mai KT, Nguyen B: Urothelial carcinoma and prostatic adenocarcinoma presenting as collision tumors. Can J Urol; 2009 Oct;16(5):4850-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urothelial carcinoma and prostatic adenocarcinoma presenting as collision tumors.
  • Urothelial carcinoma (UC) and prostatic adenocarcinoma (PAC) commonly occur in elderly patients and share common carcinogenic factors that could be identified in the urine.
  • Simultaneous occurrence of PAC and UC in the prostate is not uncommon; however, urinary bladder location of both lesions has not yet been reported.
  • All patients were diagnosed with high grade PAC and either had simultaneous at the initial diagnosis or developed UC during the follow up for PAC.
  • In conclusion, awareness of this association is important in making the correct diagnosis, especially when dealing with urinary bladder biopsy material.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Neoplasms, Multiple Primary. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Biopsy. Combined Modality Therapy. Cystoscopy. Diagnosis, Differential. Fatal Outcome. Humans. Male

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19796465.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


23. Contreras Ibáñez JA, Romero Cores P, Beltrán Ruiz-Henestrosa M: [Ocular proptosis in a patient with prostatic adenocarcinoma]. Arch Esp Urol; 2009 Jan-Feb;62(1):79-82
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ocular proptosis in a patient with prostatic adenocarcinoma].
  • [Transliterated title] Proptosis ocular en paciente con adenocarcinoma de próstata.
  • OBJECTIVE: To reach information on a rare clinical finding secondary to on infrequent location of tumour dissemination in prostatic cancer.
  • METHODS: We present a case of an adult male with ocular left proptosis and history of prostatic cancer.
  • CONCLUSIONS: In adults males, the prostatic cancer should be born in mind in the differential diagnosis of the masses in orbital location.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / secondary. Exophthalmos / etiology. Orbital Neoplasms / complications. Orbital Neoplasms / secondary. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19400453.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


24. Cotrina Monroy AP, López López A, Ruiz Solis S, Gómez Embuena A: [Incidental finding of a meningioma-en-plaque in a patient with prostate adenocarcinoma]. Rev Esp Med Nucl; 2010 Sep-Oct;29(5):254-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidental finding of a meningioma-en-plaque in a patient with prostate adenocarcinoma].
  • [Transliterated title] Hallazgo incidental de un meningioma en placa en un paciente con adenocarcinoma de próstata.
  • We present a case of a large MEP, which was an incidental finding on a scintigraphy study of a patient with prostate adenocarcinoma, this finding being histologically confirmed.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Incidental Findings. Meningeal Neoplasms / radionuclide imaging. Meningioma / radionuclide imaging. Neoplasms, Multiple Primary / radionuclide imaging. Prostatic Neoplasms / radionuclide imaging
  • [MeSH-minor] Aged. Craniocerebral Trauma / radionuclide imaging. Diagnosis, Differential. Diagnostic Errors. Exophthalmos / etiology. Headache / etiology. Humans. Magnetic Resonance Imaging. Male. Osteitis Deformans / radionuclide imaging. Radiopharmaceuticals. Skull Neoplasms / radionuclide imaging. Skull Neoplasms / secondary. Technetium Tc 99m Medronate. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier España, S.L. y SEMNIM. All rights reserved.
  • (PMID = 20398966.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


25. Lefterov SI, Gorelov SI, Krivolapov IuA: [Prognostic significance of cell proliferation, microvascular density and androgen receptor level in prostatic adenocarcinoma]. Vopr Onkol; 2009;55(6):740-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic significance of cell proliferation, microvascular density and androgen receptor level in prostatic adenocarcinoma].
  • Our study was concerned with prognostic significance of immunophenotypical features of prostate adenocarcinoma such as Ki-67 proliferation, androgen receptors (AR), microvascular density (MVD) in the stroma and tumor glands.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Neovascularization, Pathologic / metabolism. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Receptors, Androgen / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20210018.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Androgen
  •  go-up   go-down


26. Morán Pascual E, Dicapua Sacoto C, Trassierra Villa M, Pontones Moreno JL, Ruiz Cerdá JL, Jiménez Cruz JF: [Watchful waiting in incidental adenocarcinoma of the prostate]. Actas Urol Esp; 2010 Nov;34(10):854-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Watchful waiting in incidental adenocarcinoma of the prostate].
  • [Transliterated title] Actitud expectante en el adenocarcinoma incidental de próstata.
  • OBJECTIVE: To describe the outcome of patients diagnosed of incidental prostate adenocarcinoma managed by watchful waiting.
  • MATERIAL AND METHODS: We included patients with PSA< 4 ng/mL or higher with previous negative biopsy, who underwent surgery for BPH being diagnosed of incidental prostate adenocarcinoma.
  • We performed a descriptive and retrospective study in patients with this diagnosis between 1992 and 2007.
  • Progression variables were: age, preoperative and postoperative PSA, stage, Gleason score, prostate volume, initial treatment, PSA evolution and salvage treatment if necessary.
  • RESULTS: 47 patients were diagnosed of incidental prostatic adenocarcinoma, finding an incidence of 4.25%.
  • CONCLUSION: Watchful waiting is a useful option in patients with incidental prostate adenocarcinoma and favourable prognostic criteria.
  • [MeSH-major] Adenocarcinoma / therapy. Prostatic Neoplasms / therapy. Watchful Waiting

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21159280.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


27. Hussein MR, Al-Assiri M, Musalam AO: Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. Exp Mol Pathol; 2009 Apr;86(2):108-13
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma.
  • BACKGROUND: Immune cell infiltrate is a constant feature in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma.
  • This study elaborates on the cells of the immune system present in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma.
  • HYPOTHESIS: Here, we hypothesized that "the development of benign nodular prostatic hyperplasia and prostatic adenocarcinoma is associated with numeric alterations of the immune cell infiltrate".
  • MATERIALS AND METHODS: A total of 50 transurethral prostatic resection specimens, each entailing normal prostate, benign nodular prostatic hyperplasia and high grade prostatic adenocarcinoma were evaluated for the density and phenotype of the immune cells using immunohistological methods and mouse monoclonal antibodies decorating T cells (CD3), histiocytes (CD68) and B lymphocytes (CD20).
  • We observed variations in the density of the immune cells among the normal prostate, benign nodular prostatic hyperplasia and high grade prostatic adenocarcinoma.
  • Compared with normal prostate, benign nodular prostatic hyperplasia had a statistically significant high density of immune cells (3.4+/-0.4versus 13.5+/-1.0, P<0.00).
  • In contrast, a significant decrease in the counts of these cells was observed in high-grade prostatic adenocarcinoma compared to benign nodular prostatic hyperplasia (13.5+/-1.0 versus 5.2+/-0.3, P<0.01).
  • CONCLUSIONS: The increased density of immune cells (predominantly CD(+)3 T cells) in benign nodular prostatic hyperplasia suggests that the initial response to cellular damage is mediated by cell-mediated immunity.
  • The decreased density of immune cells in high-grade prostatic adenocarcinoma may reflect immunosuppression.
  • [MeSH-major] Cell Movement. Immune System / cytology. Prostate / pathology. Prostatic Hyperplasia / pathology. Prostatic Neoplasms / pathology


28. Epstein JI: Precursor lesions to prostatic adenocarcinoma. Virchows Arch; 2009 Jan;454(1):1-16
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor lesions to prostatic adenocarcinoma.
  • High-grade prostatic intraepithelial neoplasia (PIN) is the one well-documented precursor to adenocarcinoma of the prostate.
  • High-grade PIN is also differentiated from invasive acinar (usual) and ductal adenocarcinoma.
  • The incidence of high-grade PIN, its relationship to carcinoma (including molecular findings), and risk of cancer on rebiopsy are covered in detail.
  • Finally, intraductal carcinoma of the prostate, a controversial entity, is discussed and differentiated from high-grade PIN.
  • [MeSH-major] Adenocarcinoma / pathology. Precancerous Conditions / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / pathology. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Intraepithelial Neoplasia / pathology. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):840-8 [9669346.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):882-8 [17527075.001]
  • [Cites] J Clin Pathol. 2006 Apr;59(4):437-9 [16567473.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):929-33; discussion 933 [16469583.001]
  • [Cites] Urology. 1995 Dec;46(6):837-42 [7502426.001]
  • [Cites] Urology. 1997 Apr;49(4):558-63 [9111625.001]
  • [Cites] Eur Urol. 1999;35(5-6):474-8 [10325508.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12):1534-9 [11717544.001]
  • [Cites] J Urol. 2006 Jan;175(1):121-4 [16406886.001]
  • [Cites] BJU Int. 2003 Mar;91(4):350-4 [12603413.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):140-4 [10632499.001]
  • [Cites] Urology. 2004 Mar;63(3):503-8 [15028446.001]
  • [Cites] Int J Cancer. 1997 Dec 10;73(6):808-11 [9399656.001]
  • [Cites] BJU Int. 2007 Apr;99(4):765-9 [17378840.001]
  • [Cites] Hum Pathol. 1991 Jul;22(7):644-52 [1712748.001]
  • [Cites] Am J Surg Pathol. 1989 May;13(5):389-96 [2469333.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2118-24 [2004331.001]
  • [Cites] Hum Pathol. 2006 Mar;37(3):292-7 [16613324.001]
  • [Cites] Prostate. 2000 Apr 1;43(1):11-9 [10725861.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2008;11(1):20-31 [17909565.001]
  • [Cites] Hum Pathol. 2002 May;33(5):518-23 [12094377.001]
  • [Cites] Am J Surg Pathol. 1985 Aug;9(8):595-609 [4091189.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):629-33 [15105651.001]
  • [Cites] Cancer. 1969 Jan;23(1):24-34 [5763258.001]
  • [Cites] In Vivo. 1994 May-Jun;8(3):439-43 [7803731.001]
  • [Cites] Urology. 2006 Oct;68(4):800-3 [17070356.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):111-9 [2416422.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):645-59 [7686348.001]
  • [Cites] Urology. 2007 Dec;70(6):1100-3 [18158026.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1291-6 [11283929.001]
  • [Cites] Mod Pathol. 1996 Jul;9(7):742-51 [8832557.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):788-94 [2433020.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):389-91 [9458077.001]
  • [Cites] J Urol. 2000 Mar;163(3):819-23 [10687984.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):794-801 [11395558.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):873-86 [7611534.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1170-81 [15498784.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1184-8 [16931964.001]
  • [Cites] Eur Urol. 2005 Sep;48(3):379-85 [15961218.001]
  • [Cites] Prostate. 2000 Sep 1;44(4):265-70 [10951489.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):298-310 [8454275.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):389-95 [11331955.001]
  • [Cites] Am J Surg Pathol. 1986 Oct;10(10):665-71 [3766845.001]
  • [Cites] Cancer Lett. 1999 Jul 1;141(1-2):173-8 [10454259.001]
  • [Cites] Am J Surg Pathol. 2008 Jul;32(7):1060-7 [18496142.001]
  • [Cites] J Urol. 1997 Jul;158(1):12-22 [9186314.001]
  • [Cites] Hum Pathol. 2005 May;36(5):480-5 [15948114.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):802-14 [8669528.001]
  • [Cites] BJU Int. 2007 Apr;99(4):770-4 [17233800.001]
  • [Cites] BJU Int. 2004 Sep;94(4):528-33 [15329106.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1415-8 [12352407.001]
  • [Cites] Urology. 2005 Apr;65(4):745-9 [15833520.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1215-22 [9331295.001]
  • [Cites] Urology. 1997 Sep;50(3):355-9 [9301697.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):1008-13 [15297968.001]
  • [Cites] Hum Pathol. 1986 Jan;17(1):64-71 [3943853.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):435-40 [9130990.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):899-906 [16607376.001]
  • [Cites] Cancer. 1986 Oct 15;58(8):1714-9 [3756794.001]
  • [Cites] Urology. 2001 Dec;58(6):999-1003 [11744476.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 1):379-85 [8326560.001]
  • [Cites] J Urol. 2008 May;179(5):1751-5; discussion 1755 [18343427.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2617-22 [18451224.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):967-71 [10487854.001]
  • [Cites] Int J Oncol. 2005 Jan;26(1):267-74 [15586249.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1528-35 [16980940.001]
  • [Cites] J Urol. 2001 May;165(5):1409-14 [11342887.001]
  • [Cites] Prostate. 1996 Aug;29(2):117-34 [8700801.001]
  • [Cites] Neoplasia. 2006 Oct;8(10 ):826-32 [17032499.001]
  • [Cites] Am J Surg Pathol. 1992 Dec;16(12):1205-14 [1281386.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1079-85 [11474294.001]
  • [Cites] Int Urol Nephrol. 2007;39(1):189-95 [16835725.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):275-89 [15323145.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3966-71 [8508361.001]
  • [Cites] J Urol. 2005 Oct;174(4 Pt 1):1390-4; discussion 1394; author reply 1394 [16145444.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):820-34 [16469560.001]
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):147-55 [11176063.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):360-79 [14739906.001]
  • [Cites] Can J Urol. 2006 Oct;13(5):3255-60 [17076947.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1119-23 [9781651.001]
  • [Cites] J Urol. 1995 Oct;154(4):1295-9 [7544835.001]
  • (PMID = 19048290.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 85
  •  go-up   go-down


29. Chalasani V, Macek P, O'Neill GF, Barret W: Ureteric stricture secondary to unusual extension of prostatic adenocarcinoma. Can J Urol; 2010 Feb;17(1):5031-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ureteric stricture secondary to unusual extension of prostatic adenocarcinoma.
  • This article describes an unusual finding in a patient who presented with an adenocarcinoma of the prostate and right hydronephrosis.
  • Cystoscopy showed an exophytic superficial transitional cell carcinoma (TCC) of the bladder and a transrectal biopsy of the prostate confirmed adenocarcinoma Gleason score 4+3.
  • Staging investigations (CT pelvis and bone scan) were negative; androgen deprivation therapy was therefore initiated for the prostatic adenocarcinoma.
  • With a working diagnosis of upper tract TCC, right open nephroureterectomy was performed.
  • Final histology showed prostatic adenocarcinoma infiltrating the adventitia of the entire ureter up to the level of the renal pelvis.
  • A rare cause of ureteric stricture, contiguous spread of prostatic adenocarcinoma, should be considered in the differential diagnosis of patients presenting with upper tract obstruction and a known history of prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology. Ureter / pathology. Ureteral Obstruction / etiology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20156388.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


30. Torlakovic E, Lilleby W, Berner A, Torlakovic G, Chibbar R, Furre T, Fosså SD: Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma. Int J Cancer; 2005 Nov 10;117(3):381-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma.
  • The expression, distribution and the role of steroid receptors in benign and malignant untreated prostate tissues is well recognized, however, the status of steroid receptors in prostate after radiotherapy (RT) for adenocarcinoma has not yet been studied fully.
  • Immunohistochemical evaluation of androgen receptor (AR), estrogen receptor-alpha (ER-alpha), estrogen receptor-beta (ER-beta), and progesterone receptor (PR) was carried out in prostate needle biopsies obtained before and after radiotherapy from 60 patients with adenocarcinoma.
  • The ER-beta transcripts were also studied by RT-PCR in LNCaP prostate carcinoma cell line before and 24 hr after gamma-irradiation at 0.5 Gy and 8.0 Gy.
  • Significantly higher level of ER-beta expression was found in post-radiation samples of prostate adenocarcinoma and benign epithelium.
  • After RT, all steroid receptors were upregulated in prostatic stroma.
  • Although a positive association between AR and ER-beta expression was observed in pre-treatment prostate adenocarcinoma, it was lost after RT suggesting that these 2 steroid receptors respond differently to RT.
  • Upregulation of all steroid receptors in the prostate stroma and upregulation of ER-beta in the tumor epithelium after RT, may represent a protective tissue response to radiation-induced tissue injury.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / radiotherapy. Gene Expression Regulation, Neoplastic. Prostatic Neoplasms / genetics. Prostatic Neoplasms / radiotherapy. Receptors, Steroid / genetics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15900599.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Steroid
  •  go-up   go-down


31. Lavasani L, Zapanta PE, Tanna N, Sadeghi N: Metastasis of prostatic adenocarcinoma to the sphenoid sinus. Ann Otol Rhinol Laryngol; 2006 Sep;115(9):690-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of prostatic adenocarcinoma to the sphenoid sinus.
  • The presentation, diagnosis, and management of prostatic adenocarcinoma metastatic to the sphenoid sinus are reviewed.
  • A 67-year-old man with a history of prostatic adenocarcinoma presented with gradual left visual loss.
  • Operative biopsy of the lesion was significant for adenocarcinoma of the prostate.
  • When an otolaryngologist encounters a mass in the sphenoid sinus, he or she needs to consider a diverse differential diagnosis.
  • As in this clinical scenario of a patient with a history of prostatic adenocarcinoma, appropriate analysis would entail sending specimens for immunohistochemical staining, such as prostate-specific antigen and prostate-specific acid phosphatase.
  • Correct diagnosis is crucial, as these patients may achieve remission and prolonged survival with irradiation and/or hormonal therapy.
  • [MeSH-major] Adenocarcinoma / pathology. Paranasal Sinus Neoplasms / secondary. Prostatic Neoplasms / pathology. Sphenoid Sinus / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044541.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Menon S, Gujral S, Bakshi G, Tongaonkar HB: Bilateral testicular metastasis from prostatic adenocarcinoma mimicking an intertubular pattern of seminoma and expressing Rhamm. J Cancer Res Ther; 2010 Jan-Mar;6(1):97-9
Hazardous Substances Data Bank. LEUPROLIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral testicular metastasis from prostatic adenocarcinoma mimicking an intertubular pattern of seminoma and expressing Rhamm.
  • Adenocarcinoma of prostate metastasizing to testis is a rare occurrence and is incidentally detected in orchiectomy specimens.
  • A rare case of bilateral testicular metastasis of prostatic adenocarcinoma is presented wherein the metastatic cells expressed CD168, a receptor for hyaluronan mediated motility (Rhamm), implicated in the development of androgen independence in prostate cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Antigens, CD44 / biosynthesis. Extracellular Matrix Proteins / biosynthesis. Prostatic Neoplasms / pathology. Seminoma / pathology. Testicular Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Bone Neoplasms / secondary. Combined Modality Therapy. Diagnosis, Differential. Humans. Leuprolide / therapeutic use. Male. Middle Aged. Orchiectomy. Ultrasound, High-Intensity Focused, Transrectal

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479558.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antineoplastic Agents, Hormonal; 0 / Extracellular Matrix Proteins; 0 / hyaluronan-mediated motility receptor; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


33. Madaan S, Palit V, Gudgeon P, Biyani CS: Omental metastasis with malignant ascites: an unusual manifestation of prostatic adenocarcinoma. Can Urol Assoc J; 2007 Sep;1(3):288-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Omental metastasis with malignant ascites: an unusual manifestation of prostatic adenocarcinoma.
  • Omental metastasis with malignant ascites from prostatic adenocarcinoma is rare.
  • Clinical examination revealed a hard prostate and blood biochemistry demonstrated an elevated prostate specific antigen level.
  • A Doppler ultrasound scan excluded deep venous thrombosis, but a CT scan of the abdomen revealed marked para-aortic lymphadenopathy and prostate gland biopsy confirmed prostatic adenocarcinoma.
  • Histology of the omental mass showed metastasis from the prostatic adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1992 May;39(5):495-7 [1580050.001]
  • [Cites] Lymphology. 1990 Dec;23(4):183-6 [2077299.001]
  • [Cites] J Urol. 1973 Aug;110(2):232-4 [4722620.001]
  • [Cites] Urology. 2002 May;59(5):773 [11992926.001]
  • [Cites] Am J Med Sci. 2004 May;327(5):262-3 [15166746.001]
  • [Cites] Scand J Urol Nephrol. 2002;36(3):225-7 [12201941.001]
  • [Cites] Am J Med. 2001 Aug 15;111(3):245-6 [11545100.001]
  • [Cites] J Urol. 1968 Aug;100(2):183-7 [5658662.001]
  • (PMID = 18542809.001).
  • [ISSN] 1911-6470
  • [Journal-full-title] Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • [ISO-abbreviation] Can Urol Assoc J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2422958
  •  go-up   go-down


34. Constantinides C, Haritopoulos K, Anastasiou I, Dritsas C, Papamichael V, Zervas A: Multiple metastases of prostatic adenocarcinoma to the urethra after radical prostatectomy. Urol Int; 2007;79(1):92-3
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple metastases of prostatic adenocarcinoma to the urethra after radical prostatectomy.
  • We present a rare case of multiple metastases of a prostatic adenocarcinoma to the urethra.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Prostatectomy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery. Urethral Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17627178.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


35. Huan Y, Idrees M, Gribetz ME, Unger PD: Sarcomatoid carcinoma after radiation treatment of prostatic adenocarcinoma. Ann Diagn Pathol; 2008 Apr;12(2):142-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid carcinoma after radiation treatment of prostatic adenocarcinoma.
  • We report 2 patients with conventional prostatic adenocarcinoma who developed sarcomatoid carcinoma of probable prostatic origin 6 and 2.5 years after radiation treatment (seed implantation and external beam).
  • Clinically, the sarcomatoid carcinomas appeared to be of prostatic origin.
  • The pathogenesis of the tumors is still uncertain but most likely represent a radiation-induced dedifferentiation of prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carcinosarcoma / etiology. Neoplasms, Radiation-Induced / etiology. Prostatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18325477.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


36. Zeng X, Wu SF, Xu Q, Xiao Y, Liu TH: [Relationship between chromosome 8 alterations and Gleason score in prostatic adenocarcinoma]. Zhonghua Bing Li Xue Za Zhi; 2006 Sep;35(9):523-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between chromosome 8 alterations and Gleason score in prostatic adenocarcinoma].
  • OBJECTIVE: To study the gain of chromosome 8 and c-myc gene and lipoprotein lipase gene status in prostatic adenocarcinoma of Chinese patients, and to analyze the relationship between chromosome 8 alterations and Gleason score of prostatic cancer.
  • METHODS: Formalin-fixed, paraffin-embedded prostatic biopsy tissues from 34 Chinese patients with untreated prostatic adenocarcinoma were studied by three-color fluorescence in situ hybridization (FISH) using ProVysion(TM) probe kit.
  • CONCLUSIONS: Alterations in chromosome 8 are common in prostatic adenocarcinoma occurring in Chinese patients.
  • C-myc gene amplification accompanied by lipoprotein lipase gene deletion is also a common occurrence in prostatic cancer.
  • Our data suggest that chromosome 8 alterations may play some roles in the development and progression of prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Chromosome Aberrations. Chromosomes, Human, Pair 8 / genetics. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134545.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myc; EC 3.1.1.34 / Lipoprotein Lipase
  •  go-up   go-down


37. Reyes Court D, Encina S, Levy I: Prostatic adenocarcinoma with mandibular metastatic lesion: case report. Med Oral Patol Oral Cir Bucal; 2007 Oct;12(6):E424-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic adenocarcinoma with mandibular metastatic lesion: case report.
  • Differential diagnosis and treatment of these patients can be extremely difficult because there a number of pathologic conditions with similar symptoms and because diagnostic examination can be highly confusing.
  • The aim of this article is to present a case of prostatic adenocarcinoma where the only metastasis was found in the jaw.
  • [MeSH-major] Adenocarcinoma / secondary. Mandibular Neoplasms / secondary. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909506.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 13
  •  go-up   go-down


38. Xiao GQ, Burstein DE, Miller LK, Unger PD: Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma. Arch Pathol Lab Med; 2006 Jun;130(6):805-10
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma.
  • In addition to its uncertain origin, there can be diagnostic difficulty in distinguishing nephrogenic adenoma from prostatic carcinoma, particularly when dealing with lesions from the prostatic urethra.
  • OBJECTIVE: To elucidate a possible histogenic relationship between nephrogenic adenoma and renal tubules, and also to evaluate the role of immunohistochemistry in the diagnostic distinction between nephrogenic adenoma and prostate carcinoma.
  • DESIGN: Immunohistochemical studies were performed for P504S, prostate-specific antigen, CD10, p63, and epithelial membrane antigen on 9 cases of nephrogenic adenoma, 10 cases of normal renal parenchyma, and 10 cases of prostatic tissue, both benign and malignant.
  • RESULTS: Nephrogenic adenoma shares the same immunohistochemical profile as distal renal tubules: both are positive for P504S and epithelial membrane antigen and negative for p63, CD10, and prostate-specific antigen.
  • Prostatic adenocarcinoma tissue was positive for P504S and prostate-specific antigen, and normal prostatic gland tissue was positive for prostate-specific antigen and negative for P504S; p63-stained basal cells in normal prostatic gland tissue but did not react with prostatic adenocarcinoma tissue.
  • The CD10 inconsistently stained normal and neoplastic prostatic gland tissue.
  • Epithelial membrane antigen stain was negative in prostatic carcinoma, with rare occasional reactivity in normal prostatic glands.
  • Our results also demonstrated that the combination of P504S and prostate-specific antigen with epithelial membrane antigen is a valuable tool in distinguishing prostatic carcinoma from nephrogenic adenoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Immunohistochemistry / methods. Prostatic Neoplasms / diagnosis. Urologic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Male. Mucin-1 / analysis. Racemases and Epimerases / analysis. Urothelium / chemistry. Urothelium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740031.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


39. Zhang HZ, Jiang ZM, Shi L: [Pathologic characteristics of pseudohyperplastic prostatic adenocarcinoma]. Zhonghua Bing Li Xue Za Zhi; 2007 Nov;36(11):742-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathologic characteristics of pseudohyperplastic prostatic adenocarcinoma].
  • OBJECTIVE: To study the clinicopathologic features of 30 cases of pseudohyperplastic prostatic adenocarcinoma (PHPA).
  • METHODS: Eight hundred and sixty cases of ultrasound-guided prostatic needle biopsy and 46 cases of radical prostatectomy specimens collected during the period from January 1, 2005 to December 31, 2006 were retrieved from the archival files.
  • The incidence, morphology, pathologic differential diagnosis, tumor volume, preferred location and Gleason's score were studied.
  • Histologically, 66.7% of PHPA demonstrated direct transition with conventional acinar adenocarcinoma; and 76.7% of cases had coexisting conventional acinar adenocarcinoma in the remaining tissue blocks.
  • PHPA resembled benign prostate glands, in which the hyperplastic malignant acini were predominantly of medium to large size.
  • However, amongst the 20 pathologic indices of prostatic malignancy studied, occurrence of 10 or more indices exceeded 66.7%.
  • CONCLUSIONS: PHPA is not a rare phenomenon in prostatic adenocarcinoma.
  • Majority of cases have concurrent conventional acinar adenocarcinoma.
  • It is different from well-differentiated (with Gleason's score 1 or 2) adenocarcinoma with a relatively indolent clinical course.
  • In contrast, PHPA corresponds to moderately differentiated adenocarcinoma with Gleason's score of 3.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Hyperplasia / pathology. Prostatic Neoplasms / pathology. Racemases and Epimerases / metabolism
  • [MeSH-minor] Biopsy, Needle. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Diagnosis, Differential. Follow-Up Studies. Humans. Immunohistochemistry. Male. Prostatectomy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18307877.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


40. Svatek RS, Karam JA, Rogers TE, Shulman MJ, Margulis V, Benaim EA: Intraluminal crystalloids are highly associated with prostatic adenocarcinoma on concurrent biopsy specimens. Prostate Cancer Prostatic Dis; 2007;10(3):279-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraluminal crystalloids are highly associated with prostatic adenocarcinoma on concurrent biopsy specimens.
  • Prostatic crystalloids are intraluminal eosinophilic structures with variable size and shape.
  • Their presence has been described in conjunction with the occurrence of prostatic adenocarcinoma (pCA).
  • We herein report the association of crystalloids and pCA in a prospective trial utilizing an extended multi-site transrectal ultrasound-guided (TRUS) prostate biopsy protocol.
  • Indications for biopsy included a prostate-specific antigen (PSA) > or =4 ng/ml and/or abnormal digital rectal exam.
  • Overall cancer detection rate was 42.7%.
  • pCA was diagnosed in 66 (81.5%) of 81 patients with crystalloids, 70 (69.3%) of 101 patients with high-grade prostatic intraepithelial neoplasia (HGPIN), and 32 (84.2%) of 38 patients with both HGPIN and crystalloids on biopsy.
  • Multivariate analysis identified crystalloids (RR 4.53, 95% CI 2.30-8.88) and HGPIN (RR 3.20, 95% CI 1.84-5.57) as independent predictors of the presence of cancer on concurrent biopsy (P<0.001).
  • These findings suggest that the presence of crystalloids alone or in combination with HGPIN in prostate biopsies may be a more compelling indication for repeat biopsy than HGPIN alone.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor. Inclusion Bodies / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325718.001).
  • [ISSN] 1365-7852
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


41. Xiao GQ, Huan Y, Stone N, Stock R, Unger PD: Histological patterns and associated PSA levels for prostatic adenocarcinoma following brachytherapy. Pathol Res Pract; 2009;205(12):843-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological patterns and associated PSA levels for prostatic adenocarcinoma following brachytherapy.
  • A total of 60 patients with prostatic adenocarcinoma treated with brachytherapy between 1993 and 2003, who had at least one positive post-radiation biopsy, were evaluated for their morphologic patterns as well as the associated PSA levels.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy. Neoplasm Recurrence, Local. Prostate-Specific Antigen / blood. Prostatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19646822.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


42. Kruslin B, Tomas D, Rogatsch H, Reljić A, Vucić M, Balicević D, Belicza M, Mikuz G: Correlation of periacinar retraction clefting in needle core biopsies and corresponding prostatectomy specimens of patients with prostatic adenocarcinoma. Int J Surg Pathol; 2005 Jan;13(1):67-72
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of periacinar retraction clefting in needle core biopsies and corresponding prostatectomy specimens of patients with prostatic adenocarcinoma.
  • One of the underemphasized supportive criteria for the diagnosis of prostatic cancer is the presence of retraction clefting around neoplastic glands.
  • We analyzed a series of 152 prostatic cancer cases to determine the frequency, extent, and correlation of periacinar retraction clefting between needle core biopsies (NCB) and corresponding matched radical prostatectomy (RP) specimens.
  • We conclude that periacinar retraction clefting appears more frequently in neoplastic acini and could serve as a reliable criterion in the diagnosis of prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle. Prostate / pathology. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735857.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. Hameed O, Humphrey PA: Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia. Mod Pathol; 2006 Jul;19(7):899-906
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia.
  • Typically glands of prostatic adenocarcinoma have a single cell lining, although stratification can be seen in invasive carcinomas with a cribriform architecture, including ductal carcinoma.
  • The presence and diagnostic significance of stratified cells within non-cribriform carcinomatous prostatic glands has not been well addressed.
  • The histomorphological features and immunohistochemical profile of cases of non-cribriform prostatic adenocarcinoma with stratified malignant glandular epithelium were analyzed.
  • These cases were identified from needle biopsy cases from the consultation files of one of the authors and from a review of 150 consecutive in-house needle biopsy cases of prostatic adenocarcinoma.
  • The main attribute in all these foci was the presence of glandular profiles lined by several layers of epithelial cells with cytological and architectural features resembling flat or tufted high-grade prostatic intraepithelial neoplasia, but lacking basal cells as confirmed by negative 34betaE12 and/or p63 immunostains in all cases.
  • The AMACR staining profile of the stratified foci was variable, with 4 foci showing positivity, and 3 foci being negative, including two cases that displayed AMACR positivity in adjacent non-stratified prostatic adenocarcinoma.
  • Prostatic adenocarcinoma with stratified malignant glandular epithelium can be identified in prostate needle biopsy samples harboring non-cribriform prostatic adenocarcinoma and resembles glands with high-grade prostatic intraepithelial neoplasia.
  • Recognition of this pattern of prostatic adenocarcinoma is necessary to correctly diagnose such cases as invasive carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Epithelium / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / metabolism. Male. Membrane Proteins / metabolism. Middle Aged. Neoplasm Invasiveness. Prostate-Specific Antigen / blood. Racemases and Epimerases / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607376.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins; EC 3.4.21.77 / Prostate-Specific Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


44. Lotan TL, Epstein JI: Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy. Hum Pathol; 2009 Apr;40(4):471-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy.
  • Glomerulations in prostatic adenocarcinoma are characterized by dilated glands containing intraluminal cribriform structures with a single point of attachment, resembling a renal glomerulus.
  • On prostate biopsy, glomerulations are exclusively associated with carcinoma and not associated with benign mimickers.
  • We prospectively collected 45 prostate needle biopsies containing carcinoma with glomeruloid features from our consult files for a 9-month period and examined the association between glomerulations and the presence of concurrent high-grade carcinoma.
  • Glomerulations were overwhelmingly associated with high-grade cancer on the same core, composed of either Gleason pattern 4 (n = 36, 80% of cases) or Gleason pattern 5 (n = 2, 4% of cases).
  • Only a minority of glomerulations were surrounded exclusively by pattern 3 cancer (n = 7, 16% of cases) on the same core.
  • Most of the cases with surrounding pattern 4 cancer were scored as 3 + 4 = 7 (n = 24, 66%), whereas a smaller fraction were scored as 4 + 3 = 7 (n = 9, 26%), and only a minority were 4 + 4 = 8 (n = 3, 9%).
  • Glomeruloid structures are a rare but diagnostic feature of prostatic carcinoma on needle biopsy.
  • In several cases, transition could be seen among small glomerulations, large glomeruloid structures, and cribriform pattern 4 cancer.
  • These data suggest that glomerulations represent an early stage of cribriform pattern 4 cancer and, until follow-up data are available, are best graded as Gleason pattern 4.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):125-8 [5948714.001]
  • [Cites] Hum Pathol. 1998 May;29(5):543-6 [9596281.001]
  • [Cites] Mod Pathol. 1998 Jun;11(6):543-51 [9647592.001]
  • [Cites] Am J Surg Pathol. 2008 Oct;32(10):1532-9 [18724248.001]
  • [Cites] Adv Anat Pathol. 2006 Jan;13(1):57-9 [16462155.001]
  • [Cites] Hum Pathol. 2006 Mar;37(3):292-7 [16613324.001]
  • [Cites] J Clin Pathol. 2007 Jan;60(1):35-42 [17213347.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):918-24 [10435561.001]
  • (PMID = 19128819.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA058236
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS403689; NLM/ PMC3484379
  •  go-up   go-down


45. Merrimen JL, Jones G, Walker D, Leung CS, Kapusta LR, Srigley JR: Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J Urol; 2009 Aug;182(2):485-90; discussion 490
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma.
  • PURPOSE: There is debate in the literature on the role of high grade prostatic intraepithelial neoplasia as a risk factor for subsequent prostatic adenocarcinoma detection on prostatic needle biopsy.
  • We determined whether high grade prostatic intraepithelial neoplasia on initial prostatic needle biopsy is an independent risk factor for prostatic adenocarcinoma and whether differences exist between prostatic adenocarcinoma in patients with previous high grade prostatic intraepithelial neoplasia and those with a benign diagnosis.
  • MATERIALS AND METHODS: Pathological findings in prostatic needle biopsies in 12,304 men who underwent initial prostatic needle biopsy in an 8-year period were analyzed.
  • Patients were included in the analysis when the initial diagnosis was high grade prostatic intraepithelial neoplasia alone or a benign diagnosis and at least 1 followup prostatic needle biopsy was performed.
  • The primary study outcome was prostatic adenocarcinoma and secondary outcome measurements were cancer characteristics, such as Gleason score and extent of tissue involvement with prostatic adenocarcinoma.
  • RESULTS: In the high grade prostatic intraepithelial neoplasia group of 564 patients and the benign group of 845, 27.48% and 22.01%, respectively, were diagnosed with prostatic adenocarcinoma on followup prostatic needle biopsy (p = 0.02).
  • When age, prostate specific antigen and sampling extent were adjusted for, the adenocarcinoma risk after an initial diagnosis of high grade prostatic intraepithelial neoplasia remained significant (OR 1.38, p = 0.03).
  • The risk was related to the extent of high grade prostatic intraepithelial neoplasia in the initial sample with a greater likelihood of adenocarcinoma when multiple prostatic sites were involved by high grade prostatic intraepithelial neoplasia.
  • Patients in whom prostatic adenocarcinoma developed after a benign diagnosis on initial prostatic needle biopsy had greater tumor volume.
  • However, mean followup was longer in the benign group than in the high grade prostatic intraepithelial neoplasia group (2.35 vs 1.36 years).
  • CONCLUSIONS: Patients with an initial diagnosis of high grade prostatic intraepithelial neoplasia, especially when multifocal, are at greater risk for subsequent prostatic adenocarcinoma than those with a benign diagnosis.
  • Results suggest that followup should be more rigorous in patients with multifocal high grade prostatic intraepithelial neoplasia.
  • [MeSH-major] Adenocarcinoma / epidemiology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / epidemiology. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19524976.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Trivunić S, Budakov P, Vucković N, Zivojinov M: [Morphological parameters of prostatic adenocarcinoma]. Med Pregl; 2007 Nov-Dec;60(11-12):549-52
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphological parameters of prostatic adenocarcinoma].
  • INTRODUCTION: Prostatic carcinoma is one of the most common malignancies in men and the second most common cause of cancer-related deaths, after lung cancer.
  • PROSTATIC CARCINOMA: HISTOLOGIC FEATURES: Prostatic carcinomas have multiple histologic patterns, which can easily be confused with benign lesions.
  • The following histologic changes are associated with prostatic carcinomas. prostatic acini are close to one another and present with linear infiltrates in the fibromuscular tissue; cells lining the acini often consist of a single layer, and the basal cell layer is absent; prominent large eosinophilic nucleoli are usually present in malignant cells; nuclear hyperchromatism is rare and it depends on the quality of the tissue fixation; perineural invasion is often observed.
  • Immunohistochemistry is widely used in pathology and clinical diagnosis of prostatic carcinoma, metastases of prostatic origin in staging malignant tumors and in the prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18666594.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


47. Montironi R, Ball RY, Griffiths DF, Grigor K, Harnden PM, Jarmulowicz M, McWilliam LJ, Moseley RP, Parkinson MC, Santinelli A, Moss SM, Melia JW: Bayesian belief network for the Gleason patterns in prostatic adenocarcinoma: development of a diagnostic decision support system for educational purposes. Anal Quant Cytol Histol; 2008 Feb;30(1):8-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bayesian belief network for the Gleason patterns in prostatic adenocarcinoma: development of a diagnostic decision support system for educational purposes.
  • OBJECTIVE: To develop a Bayesian belief network (BBN) for Gleason grading of prostate adenocarcinoma.
  • -based investigation of observer reproducibility of Gleason grading of prostatic biopsies were used.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Decision Support Systems, Clinical. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology
  • [MeSH-minor] Bayes Theorem. Humans. Male. Neoplasm Staging. Observer Variation. Pathology, Clinical / education. Prostate. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459582.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501019
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


48. Hosseini SY, Danesh AK, Parvin M, Basiri A, Javadzadeh T, Safarinejad MR, Nahabedian A: Incidental prostatic adenocarcinoma in patients with PSA less than 4 ng/mL undergoing radical cystoprostatectomy for bladder cancer in Iranian men. Int Braz J Urol; 2007 Mar-Apr;33(2):167-73; discussion 173-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental prostatic adenocarcinoma in patients with PSA less than 4 ng/mL undergoing radical cystoprostatectomy for bladder cancer in Iranian men.
  • OBJECTIVE: To assess the incidence of prostate adenocarcinoma in patients undergoing radical cystoprostatectomy due to bladder cancer in Iranian men.
  • MATERIALS AND METHODS: Fifty cystoprostatectomy specimens removed due to bladder malignancy (2004-2005) at two referral centers (Shaheed Modarress and Shaheed Labbafinejad Hospitals, Tehran, Iran) were examined for the coincidental finding of prostate cancer (PCa).
  • Pathologic grade, stage, morphometric volume, number of tumor foci and association with areas of high grade prostatic intraepithelial neoplasia (HGPIN) were assessed by light microscopy.
  • RESULTS: Incidentally detected cancer was found in 7 (14%) of cystoprostatectomy specimens.
  • HGPIN was present in 1 (14.3%) of the cystoprostatectomies with incidentally detected prostate cancer.
  • None of cystoprostatectomies without prostate cancer had HGPIN.
  • CONCLUSION: We conclude that incidentally detected prostate cancer in Iran is lower than the rates reported in other countries.
  • Further studies are warranted for better declaration of variability of prostate cancer between different ethnic groups.
  • [MeSH-major] Adenocarcinoma / diagnosis. Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery


49. Primavera V, Querques G, Guigui B, Turco I, Iaculli C, Russo V, Delle Noci N: [Choroidal metastasis from clinically regressed prostate adenocarcinoma: imaging of a rare case]. J Fr Ophtalmol; 2008 Nov;31(9):877-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choroidal metastasis from clinically regressed prostate adenocarcinoma: imaging of a rare case].
  • [Transliterated title] Métastase choroïdienne d'un adénocarcinome de la prostate: iconographie d'un cas rare.
  • We report a rare case of prostatic adenocarcinoma metastases at the choroids, diagnosed and followed by fluorescein angiography (FA), indocyanine-green angiography (ICGA), and optical coherence tomography (OCT-3 Stratus).
  • The systemic workup, including hematologic analysis and total-body computed tomography (CT), revealed elevated serum prostate-specific antigen (PSA) and alkaline phosphatase, extensive abnormalities of the axial skeleton, and nodular pulmonary shadows; therefore, prostatic adenocarcinoma was suspected.
  • Needle biopsies (prostatic and pulmonary) confirmed adenocarcinoma of the prostate, with metastatic disease.
  • DISCUSSION: Prostatic carcinoma should be considered in any male patient with a choroidal mass suspected of being a metastasis.
  • In our patient, FA, ICGA, and OCT clearly documented the complete regression of choroidal metastasis from prostatic carcinoma.
  • Fluorescein angiography, indocyanine-green angiography, and optical coherence tomography are useful tools in the diagnosis and follow-up of prostatic adenocarcinoma metastatic to the choroid.
  • [MeSH-major] Adenocarcinoma / secondary. Choroid Neoplasms / secondary. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19107059.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


50. Winkler MH, Livni N, Mannion EM, Hrouda D, Christmas T: Characteristics of incidental prostatic adenocarcinoma in contemporary radical cystoprostatectomy specimens. BJU Int; 2007 Mar;99(3):554-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of incidental prostatic adenocarcinoma in contemporary radical cystoprostatectomy specimens.
  • OBJECTIVES: To investigate the relationship between prostate-specific antigen (PSA) level and tumour volume for incidental adenocarcinoma of the prostate found in cystoprostatectomy (CP) specimens, and to analyse the incidence of clinically significant prostate cancers in CP specimens and the biochemical recurrence of incidental prostate cancers on short-term follow up.
  • None of the patients had any evidence of prostate cancer before CP.
  • RESULTS: Incidental prostate cancer was detected in 58 of 97 (60%) of the CP specimens; of these, 31 (53%) were significant according to the definition of Stamey et al.
  • The median PSA level for patients with and without prostate cancer was not significantly different (3.1 vs 1.1 ng/mL, P = 0.06).
  • The follow-up of the 35 patients alive with prostate cancer showed four PSA recurrences (PSA >0.02 ng/mL) with one distant metastasis after a median follow-up of 3 years.
  • CONCLUSIONS: The weak correlation between PSA level and tumour volume in these patients supports the argument that PSA is largely produced by benign prostatic hyperplasia and is therefore a poor screening tool for asymptomatic healthy men.
  • Most incidental prostate cancers in CP specimens are significant, contrary to previous analyses, but have little practical importance in terms of oncological outcome.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Cystectomy / methods. Follow-Up Studies. Humans. Incidental Findings. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prospective Studies. Prostate-Specific Antigen / blood. Prostatectomy / methods

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17407514.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


51. Tsujino K, Sasada S, Kawahara K, Terada H, Komori C, Suzuki H, Okamoto N, Kobayashi M, Hirashima T, Matsui K, Kawase I: [A case of prostatic adenocarcinoma clinically presenting as supraclavicular and mediastinal lymphadenopathy]. Nihon Kokyuki Gakkai Zasshi; 2007 Aug;45(8):648-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of prostatic adenocarcinoma clinically presenting as supraclavicular and mediastinal lymphadenopathy].
  • We report a 70-year-old man with prostatic carcinoma presenting as supraclaviculer and mediastinal lymphadenopathy.
  • He had no urinary tract symptoms, and computed tomography and FDG-PET showed no abnormality in the prostate or pelvic lymph nodes.
  • Metastatic prostatic adenocarcinoma was finally diagnosed from the results of immunohistochemical staining for PSA of a biopsy specimen of the mediastinal lymph node, and he was treated by hormonal therapy.
  • There are fears that some other similar cases might be treated with chemotherapy as lung cancer without immunohistochemical staining.
  • Prostatic carcinoma should always be considered in the differential diagnosis of elderly men with supraclaviculer or mediastinal lymph node metastases, since appropriate treatment will lead to a prolonged survival.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lymph Nodes / pathology. Lymphatic Diseases / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy, Needle. Humans. Lymphatic Metastasis. Male. Mediastinum. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17763696.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


52. Bantis A, Gonidi M, Athanassiades P, Tsolos Ch, Liossi A, Aggelonidou E, Athanassiadou AM, Petrakakou E, Athanassiadou P: Prognostic value of DNA analysis of prostate adenocarcinoma: correlation to clinicopathologic predictors. J Exp Clin Cancer Res; 2005 Jun;24(2):273-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of DNA analysis of prostate adenocarcinoma: correlation to clinicopathologic predictors.
  • The ability to accurately predict tumor behavior and patient survival is a problem in managing patients with prostate cancer.
  • DNA ploidy provides important information for the evaluation of the prognosis of prostate cancer.
  • The aim of this study was to investigate the DNA ploidy in imprints from prostate adenocarcinomas in a group of 70 patients in relation to Gleason score, tumor differentiation, stage and PSA serum levels.
  • Our results conclude that DNA ploidy status appears to be an additional marker in the field of prognosis of prostatic adenocarcinoma and could provide useful information on the potential behavior of prostate cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. DNA / metabolism. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110761.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 9007-49-2 / DNA
  •  go-up   go-down


53. Murugan P, Brown RE, Zhao B: Nonspecific granulomatous prostatitis with prostatic adenocarcinoma. Indian J Pathol Microbiol; 2010 Jan-Mar;53(1):152-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonspecific granulomatous prostatitis with prostatic adenocarcinoma.
  • Such cases may be mistaken for adenocarcinoma clinically and radiologically.
  • Histological resemblance to adenocarcinoma may arise when there is a xanthogranulomatous pattern or a prominence of epithelioid histiocytes.
  • However, NSGP may rarely coexist with adenocarcinoma and it is critical to sample these cases thoroughly to exclude the presence of malignancy.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Prostatic Neoplasms / complications. Prostatic Neoplasms / diagnosis. Prostatitis / complications. Prostatitis / diagnosis

  • Genetic Alliance. consumer health - Prostatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20090250.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


54. Patton KT, Chen HM, Joseph L, Yang XJ: Decreased annexin I expression in prostatic adenocarcinoma and in high-grade prostatic intraepithelial neoplasia. Histopathology; 2005 Dec;47(6):597-601

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased annexin I expression in prostatic adenocarcinoma and in high-grade prostatic intraepithelial neoplasia.
  • AIMS: To analyse annexin I expression in prostatic carcinoma.
  • The decreased expression of annexin I, II and VII proteins has been reported in different types of cancer.
  • METHODS AND RESULTS: Using immunohistochemistry, we analysed annexin I expression in 77 cases of prostatic adenocarcinoma (Gleason score 6, N = 40; Gleason scores 7-8, N = 27; and Gleason scores 9-10, N = 10) and high-grade prostatic intraepithelial neoplasia (PIN, N = 50).
  • In contrast to positive staining in adjacent benign prostatic epithelium, annexin I expression was decreased (focally positive) in 76% of cases of high-grade PIN (P < 0.0001) and was decreased or absent in 81% of prostatic adenocarcinomas (P < 0.0001).
  • CONCLUSIONS: Expression of annexin I inversely correlates with the increasing histological grade of prostatic adenocarcinoma.
  • By showing a progressive loss of annexin I expression in high-grade PIN, intermediate-grade and high-grade cancer, our findings suggest that the loss of annexin I expression occurs early in prostatic tumorigenesis and becomes more prominent throughout tumour progression.
  • The loss of expression of annexin I may serve as a useful marker of prostate cancer development and progression.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Annexin A1 / analysis. Biomarkers, Tumor / analysis. Prostatic Intraepithelial Neoplasia / genetics. Prostatic Intraepithelial Neoplasia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324197.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A1; 0 / Biomarkers, Tumor
  •  go-up   go-down


55. Mai KT, Burns BF, Stinson WA, Morash C: The 3-dimensional structure of isolated and small foci of prostatic adenocarcinoma: the morphologic relationship between prostatic adenocarcinoma and prostatic intraepithelial neoplasia. Appl Immunohistochem Mol Morphol; 2007 Mar;15(1):50-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The 3-dimensional structure of isolated and small foci of prostatic adenocarcinoma: the morphologic relationship between prostatic adenocarcinoma and prostatic intraepithelial neoplasia.
  • BACKGROUND: Transitional histopathologic changes from high-grade prostatic intraepithelial neoplasia (HGPIN) into early prostatic adenocarcinoma (PAC) have not been well studied to date.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536307.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Cibull TL, Jones TD, Li L, Eble JN, Ann Baldridge L, Malott SR, Luo Y, Cheng L: Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J Clin Pathol; 2006 Mar;59(3):285-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of Pim-1 during progression of prostatic adenocarcinoma.
  • Recently, evidence has shown Pim-1 to be important in prostatic carcinogenesis.
  • In order to further our understanding of its role in prostate cancer, we investigated Pim-1 expression in normal, premalignant, and malignant prostate tissue.
  • METHODS: Using immunohistochemistry, Pim-1 expression was analysed in prostate tissue from 120 radical prostatectomy specimens.
  • In each case, Pim-1 staining was evaluated in benign prostatic epithelium, high grade prostatic intraepithelial neoplasia (PIN), and prostatic adenocarcinoma.
  • RESULTS: Pim-1 immunoreactivity was identified in 120 cases (100%) of adenocarcinoma, 120 cases (100%) of high grade PIN, and 62 cases (52%) of benign glands.
  • The number of cells staining in benign epithelium (mean 34%) was much lower than that in high grade PIN (mean 80%; p<0.0001) or adenocarcinoma (mean, 84%; p<0.0001).
  • There was no significant difference between high grade PIN and adenocarcinoma in the percentage of cells staining positively for Pim-1 (p = 0.34).
  • The staining intensity for Pim-1 was significantly lower in benign prostatic epithelium than in PIN and adenocarcinoma (p<0.001).
  • CONCLUSIONS: Pim-1 expression is elevated in PIN and prostatic adenocarcinoma compared with benign prostatic epithelium.
  • This finding suggests that upregulation of Pim-1 may play a role in prostatic neoplasia.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Prostatic Neoplasms / chemistry. Proto-Oncogene Proteins c-pim-1 / analysis
  • [MeSH-minor] Aged. Analysis of Variance. Disease Progression. Humans. Male. Middle Aged. Neoplasm Staging. Prostatectomy. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / surgery. Prostatic Intraepithelial Neoplasia / chemistry. Prostatic Intraepithelial Neoplasia / surgery. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2003 Sep;4(3):223-38 [14522256.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1301-9 [13679438.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8079-84 [14678956.001]
  • [Cites] Blood. 2004 May 15;103(10):3744-50 [14764533.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3064-8 [15131044.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2362-6 [15160339.001]
  • [Cites] J Urol. 1974 Jan;111(1):58-64 [4813554.001]
  • [Cites] J Biol Chem. 1999 Jun 25;274(26):18659-66 [10373478.001]
  • [Cites] Oncogene. 1999 Jul 8;18(27):4022-31 [10435626.001]
  • [Cites] J Urol. 2000 Jun;163(6):1751-5 [10799175.001]
  • [Cites] Int Immunol. 2000 Oct;12(10):1389-96 [11007756.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] J Immunol. 2002 Feb 15;168(4):1524-7 [11823475.001]
  • [Cites] Am J Pathol. 2002 Feb;160(2):667-71 [11839587.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):153-9 [12185366.001]
  • [Cites] Oncogene Res. 1987 Jun;1(1):87-101 [3329711.001]
  • [Cites] Mol Cell Biol. 1988 Apr;8(4):1498-503 [2837645.001]
  • [Cites] J Urol. 1991 Feb;145(2):324-8; discussion 328-9 [1988723.001]
  • [Cites] EMBO J. 1991 Mar;10(3):655-64 [1825810.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2486-9 [1826633.001]
  • [Cites] Am J Pathol. 1996 May;148(5):1375-80 [8623909.001]
  • [Cites] Arch Biochem Biophys. 1996 Jun 15;330(2):259-65 [8660654.001]
  • [Cites] Oncogene. 1997 Sep 18;15(12):1471-80 [9333023.001]
  • [Cites] Cell Growth Differ. 1997 Dec;8(12):1371-80 [9419425.001]
  • [Cites] J Natl Cancer Inst. 1998 Feb 4;90(3):233-7 [9462681.001]
  • [Cites] EMBO J. 1998 Sep 15;17(18):5349-59 [9736613.001]
  • [Cites] Mol Cell. 1998 Oct;2(4):417-25 [9809063.001]
  • [Cites] J Vet Sci. 2001 Dec;2(3):167-79 [12441685.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2271-6 [14633601.001]
  • (PMID = 16505280.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.11.1 / Proto-Oncogene Proteins c-pim-1
  • [Other-IDs] NLM/ PMC1860332
  •  go-up   go-down


57. Madabhushi A, Feldman MD, Metaxas DN, Tomaszeweski J, Chute D: Automated detection of prostatic adenocarcinoma from high-resolution ex vivo MRI. IEEE Trans Med Imaging; 2005 Dec;24(12):1611-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Automated detection of prostatic adenocarcinoma from high-resolution ex vivo MRI.
  • Prostatic adenocarcinoma is the most commonly occurring cancer among men in the United States, second only to skin cancer.
  • Currently, the only definitive method to ascertain the presence of prostatic cancer is by trans-rectal ultrasound (TRUS) directed biopsy.
  • High-resolution magnetic resonance imaging (MRI) has been shown to have a higher accuracy of prostate cancer detection compared to ultrasound.
  • Consequently, several researchers have been exploring the use of high resolution MRI in performing prostate biopsies.
  • Visual detection of prostate cancer, however, continues to be difficult owing to its apparent lack of shape, and the fact that several malignant and benign structures have overlapping intensity and texture characteristics.
  • In this paper, we present a fully automated computer-aided detection (CAD) system for detecting prostatic adenocarcinoma from 4 Tesla ex vivo magnetic resonance (MR) imagery of the prostate.
  • We evaluated our CAD system on a total of 33 two-dimensional (2-D) MR slices from five different 3-D MR prostate studies.
  • Future work will focus on extending the methodology to guide high-resolution MRI-assisted in vivo prostate biopsies.
  • [MeSH-major] Adenocarcinoma / pathology. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Imaging, Three-Dimensional / methods. Magnetic Resonance Imaging / methods. Pattern Recognition, Automated / methods. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16350920.001).
  • [ISSN] 0278-0062
  • [Journal-full-title] IEEE transactions on medical imaging
  • [ISO-abbreviation] IEEE Trans Med Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Altinok G, Powell IJ, Che M, Hormont K, Sarkar FH, Sakr WA, Grignon D, Liao DJ: Reduction of QM protein expression correlates with tumor grade in prostatic adenocarcinoma. Prostate Cancer Prostatic Dis; 2006;9(1):77-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of QM protein expression correlates with tumor grade in prostatic adenocarcinoma.
  • The present study is the first report on immunohistochemical data of QM in human prostatic tissues.
  • Paraffin sections of human prostate cancer samples were immunohistochemically stained for QM.
  • QM protein expression was found in all normal prostate glands adjacent to prostate cancer and in various intraepithelial neoplasia (PIN).
  • In prostate cancer, the staining intensity and stained areas were decreased, compared to the normal glands and PIN lesions; in high-grade tumors only some patches of tumor cells showed positivity.
  • Moreover, staining in prostatic adenocarcinoma was often topographically patchy and varied from negative or weak (1+) to intense (3+).
  • This preliminary study suggests that decreased QM expression may be associated with early development of prostate cancer, but later a high level of QM may facilitate progression of the tumors to a more aggressive phenotype.
  • [MeSH-major] Adenocarcinoma / metabolism. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Neoplasms / metabolism. Ribosomal Proteins / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16331298.001).
  • [ISSN] 1365-7852
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ribosomal Proteins; 0 / Tumor Suppressor Proteins; 0 / ribosomal protein L10
  •  go-up   go-down


59. Mahmoodi M, Zhang S, Salim S, Hou JS, Garcia FU: Lipofuscin pigment can be used as a prognostic marker in prostatic adenocarcinoma. Ann Diagn Pathol; 2006 Oct;10(5):257-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipofuscin pigment can be used as a prognostic marker in prostatic adenocarcinoma.
  • It is also present in prostatic adenocarcinoma.
  • The purpose of this study is to evaluate the prognostic significance of lipofuscin in prostatic adenocarcinoma.
  • The adenocarcinoma cases were divided into lipofuscin-positive group and lipofuscin-negative group.
  • Lipofuscin pigment was found in 17 (31%) of 60 prostatic adenocarcinomas as random, sparse, fine, yellow-brown intracytoplasmic granules staining positive for cathepsin D and negative for S-100 protein.
  • Lipofuscin in prostatic adenocarcinoma correlates with both lower Gleason score and pathologic stage.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Lipofuscin / metabolism. Prostatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979516.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Lipofuscin; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


60. Abaza R, Diaz LK Jr, Laskin WB, Pins MR: Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy. J Urol; 2006 Dec;176(6 Pt 1):2701-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
  • PURPOSE: Discovery of prostatic adenocarcinoma limited to transurethral resection material generates a treatment dilemma.
  • We investigated the usefulness of parameters shown to be associated with prognosis in prostate cancer (p53 and bcl-2 immuno-expression, DNA cell cycle analysis and Gleason score) to stratify these incidentally identified tumors to guide clinical decision making.
  • MATERIALS AND METHODS: Paraffin embedded tissues from transurethral prostate resection specimens containing T1a prostate adenocarcinoma from 44 patients who underwent resection between 1980 and 1990 were immunostained for p53 and bcl-2, and subjected to flow cytometry to determine DNA ploidy.
  • Statistical relationships among these 4 variables, tumor progression and cancer specific survival were analyzed.
  • RESULTS: Six of 44 patients in the study population had cancer progression.
  • Only 2 tumors studied were aneuploid and neither of these 2 patients had cancer progression.
  • Only Gleason score was a significant predictor of cancer progression on univariate and multivariate Cox regression analysis (p = 0.045 and 0.046, respectively).
  • CONCLUSIONS: For T1a prostate cancer incidentally detected on transurethral prostate resection p53 and bcl-2 immuno-expression, and DNA ploidy do not predict survival or disease progression.
  • [MeSH-major] Adenocarcinoma / genetics. Incidental Findings. Prostatectomy. Prostatic Neoplasms / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Disease Progression. Flow Cytometry. Humans. Immunohistochemistry. Male. Middle Aged. Ploidies. Prognosis. Prostatic Diseases / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085199.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


61. Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, Koch MO: Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. J Urol; 2005 Dec;174(6):2181-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
  • PURPOSE: Gleason grade and tumor stage are well established prognostic factors in prostate cancer.
  • Histological demonstration of tumor in lymphovascular spaces has been associated with poor prognosis in many tumor types but it is not included in current prostate cancer grading and staging schemes.
  • Whether lymphovascular invasion is an independent prognostic factor for disease progression in prostate cancer is uncertain.
  • We retrospectively investigated lymphovascular invasion as a predictive factor for biochemical failure and cancer specific survival following radical prostatectomy.
  • MATERIALS AND METHODS: The records of 504 patients with prostatic adenocarcinoma undergoing radical prostatectomy were reviewed for lymphovascular invasion.
  • Univariate analysis showed a significant association between lymphovascular invasion and higher preoperative serum prostate specific antigen (PSA), advanced pathological stage, higher Gleason score, positive surgical margins, extraprostatic extension, seminal vesicle invasion, lymph node metastasis and perineural invasion (each p <0.001).
  • No association was observed between lymphovascular invasion and patient age at surgery, prostate weight or high grade prostatic intraepithelial neoplasia.
  • Lymphovascular invasion was an independent predictor of PSA recurrence (HR 1.6, 95% CI 1.12 to 2.38, p = 0.01) and cancer specific survival (HR 2.75, 95% CI 1.04 to 2.28, p = 0.041) after controlling for tumor stage, surgical margins and Gleason grade on multivariate analysis.
  • Five-year cancer specific survival was 90% in men with lymphovascular invasion compared to 98% in those without lymphovascular invasion (p <0.001).
  • CONCLUSIONS: Lymphovascular invasion can be identified in approximately 20% of prostate cancer cases.
  • Lymphovascular invasion is an independent risk factor for PSA recurrence and cancer death in patients with prostate cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphatic Vessels / pathology. Prostatectomy. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Disease-Free Survival. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Medical Records. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Prostate-Specific Antigen / blood. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16280760.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


62. Tseng TY, Sevilla DW, Moul JW, Maloney KE: Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report. Prostate Cancer Prostatic Dis; 2006;9(2):195-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report.
  • A 65-year-old man with a history of combined pelvic external beam radiation therapy (EBRT) and brachytherapy for prostatic adenocarcinoma 15 years prior underwent total pelvic exenteration for presumed rectal sarcoma with prostatic invasion.
  • Pathology revealed carcinosarcoma of prostatic origin.
  • This patient exhibited the longest reported interval between initial presentation with prostatic adenocarcinoma and development of carcinosarcoma.
  • This case is also the first reported case of prostatic carcinosarcoma occurring after combined EBRT and brachytherapy.
  • The increasing use of such combination high-dose radiation therapy may potentially lead to an increased incidence of secondary malignancies such as prostatic carcinosarcoma in the future.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carcinosarcoma / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Multiple Primary / pathology. Prostatic Neoplasms / radiotherapy. Rectal Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Brachytherapy / methods. Combined Modality Therapy. Follow-Up Studies. Humans. Immunohistochemistry. Iridium Radioisotopes / therapeutic use. Male. Neoplasm Staging. Neoplasms, Radiation-Induced / pathology. Neoplasms, Radiation-Induced / surgery. Pelvic Exenteration. Prostate-Specific Antigen / blood. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16568146.001).
  • [ISSN] 1365-7852
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iridium Radioisotopes; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


63. Ulamec M, Tomas D, Ensinger C, Cupic H, Belicza M, Mikuz G, Kruslin B: Periacinar retraction clefting in proliferative prostatic atrophy and prostatic adenocarcinoma. J Clin Pathol; 2007 Oct;60(10):1098-101
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periacinar retraction clefting in proliferative prostatic atrophy and prostatic adenocarcinoma.
  • AIMS: To evaluate the presence and extent of periacinar retraction clefting in proliferative prostatic atrophy and carcinoma in radical prostatectomy specimens.
  • According to the presence and extent of periacinar retraction clefting, atrophic and neoplastic glands were classified as: group 1, glands without clefts or with clefts affecting <or=50% of gland circumference; group 2, glands with clefts that affected >50% of the circumference in <50% of examined glands; and group 3, glands with clefts that affected >50% of the circumference in >or=50% of examined glands.
  • RESULTS: Forty-four (88.0%) atrophic foci were without periacinar clefts or clefts were present in less than half of the gland circumference (group 1).
  • In 6 (12.0%), atrophic foci clefts affected >50% of gland circumference (groups 2 and 3).
  • Forty-five (90.0%) carcinomas were with clefts which affected more than 50% of gland circumference (groups 2 and 3); and in five carcinomas only, clefts were not found or affected <50% of gland circumference (group 1).
  • CONCLUSION: Results indicate that periacinar retraction clefting represents a reliable criterion in differential diagnosis between proliferative atrophy and carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Hyperplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Atrophy / pathology. Diagnosis, Differential. Humans. Male. Middle Aged. Prostate / pathology. Prostatectomy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prostate. 2004 Dec 1;61(4):324-31 [15389817.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):328-48 [14976539.001]
  • [Cites] Mod Pathol. 1998 Jan;11(1):47-54 [9556422.001]
  • [Cites] AMA Arch Pathol. 1953 Feb;55(2):131-41 [13007281.001]
  • [Cites] Int J Surg Pathol. 2005 Jan;13(1):67-72 [15735857.001]
  • [Cites] Urology. 2005 Apr;65(4):745-9 [15833520.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):874-80 [15958851.001]
  • [Cites] Eur Urol. 2005 Oct;48(4):546-51 [16046052.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):835-43 [16740037.001]
  • [Cites] BJU Int. 2006 Jul;98(1):184-8 [16831166.001]
  • [Cites] Am J Surg Pathol. 2006 Oct;30(10):1281-91 [17001160.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2006;9(4):414-9 [16652121.001]
  • [Cites] Eur Urol. 2007 Jan;51(1):98-103; discussion 103-4 [16824675.001]
  • [Cites] Pathol Oncol Res. 2006;12(4):205-9 [17189982.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1985-92 [10595928.001]
  • [Cites] Urology. 2000 Nov 1;56(5):828-32 [11068311.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1767-73 [11337374.001]
  • [Cites] Arch Pathol Lab Med. 2002 May;126(5):554-61 [11958660.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2912-23 [12231536.001]
  • [Cites] Virchows Arch. 2003 Oct;443(4):524-7 [12898245.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 2):S36-40 [14713751.001]
  • [Cites] Am J Surg Pathol. 1995 Sep;19(9):1068-76 [7544958.001]
  • (PMID = 17298985.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2014863
  •  go-up   go-down


64. Cossu-Rocca P, Contini M, Brunelli M, Festa A, Pili F, Gobbo S, Eccher A, Mura A, Massarelli G, Martignoni G: S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma. Am J Surg Pathol; 2009 Jul;33(7):1031-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma.
  • In addition to its uncertain origin, there can be diagnostic difficulty in distinguishing nephrogenic adenoma from prostatic adenocarcinoma, particularly with lesions arising in the prostatic urethra.
  • Alpha-methylacyl-CoA racemase (AMACR), a recently identified prostate cancer marker, has also been found to be expressed in renal tubules and in some renal epithelial neoplasms.
  • In this study, we investigated the expression of S100A1 and AMACR in 18 nephrogenic adenomas and in 100 prostatic adenocarcinomas.
  • A strong and distinct cytoplasmic or nucleocytoplasmic staining of S100A1 was found in 17 out of 18 cases of nephrogenic adenoma (94%), but never in prostatic adenocarcinoma.
  • In contrast, AMACR expression was detected in 14 of 18 nephrogenic adenomas (78%) and in 96 of 100 prostatic adenocarcinomas (96%).
  • We conclude that (1) S100A1 is a specific and sensitive immunohistochemical marker to differentiate nephrogenic adenoma from prostatic adenocarcinoma;.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Prostatic Neoplasms / diagnosis. S100 Proteins / biosynthesis. Urogenital Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Racemases and Epimerases / biosynthesis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19384190.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins; 0 / S100A1 protein; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


65. Miller JS, Chen Y, Ye H, Robinson BD, Brimo F, Epstein JI: Extraprostatic extension of prostatic adenocarcinoma on needle core biopsy: report of 72 cases with clinical follow-up. BJU Int; 2010 Aug;106(3):330-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraprostatic extension of prostatic adenocarcinoma on needle core biopsy: report of 72 cases with clinical follow-up.
  • OBJECTIVE: To describe the histological findings and prognosis that are associated with extraprostatic extension (EPE) on needle core biopsy of prostatic adenocarcinoma.
  • PATIENTS AND METHODS: We retrieved 99 cases of prostatic adenocarcinoma with EPE at initial diagnosis on biopsy from the consultation files of one of the authors between 1997 and 2009.
  • RESULTS: The mean (range) age of the patients was 64 (48-87) years, the median (mean, range) serum prostatic specific antigen level was 7.8 (64.8, 0.3-1505) ng/mL, and 60 of the patients (83%) had abnormalities on a digital rectal examination.
  • CONCLUSION: EPE on needle core biopsy of the prostate is strongly associated with extensive, high-grade prostatic adenocarcinoma, such that its usefulness as an isolated prognostic factor is relatively limited.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Prostate-Specific Antigen / blood. Prostatectomy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20002671.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


66. Mentor-Marcel R, Lamartiniere CA, Eltoum IA, Greenberg NM, Elgavish A: Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). J Nutr; 2005 May;135(5):989-95
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP).
  • Studies in vitro suggest that osteopontin (OPN), an extracellular matrix protein secreted by macrophages infiltrating prostate tumors, and by tumor cells, may have a role in the transition from clinically insignificant tumors to metastatic prostate cancer (PC).
  • Our earlier studies in TRAnsgenic Mouse Prostate adenocarcinoma (TRAMP) mice showed that genistein, an isoflavone found in soybeans, lowered the incidence of advanced PC.
  • Administration of 250 and 500 mg genistein/kg AIN-76A improved survival (P = 0.008 and P = 0.005, respectively) and reduced mean weight of prostates with poorly differentiated cancer (PD) (P < 0.001), as well as the mean weight of periaortic lymph nodes (LN), although the latter was not significant.
  • OPN mRNA levels in the dorsolateral prostate and metastasis to LN were significantly correlated (r = 0.643; P = 0.00006).
  • Genistein had a dose-dependent, significant inhibitory effect on OPN transcript levels in prostates displaying advanced prostate cancer (PD; score 6; P = 0.05).
  • [MeSH-major] Adenocarcinoma / genetics. Genistein / pharmacology. Prostatic Neoplasms / genetics. Sialoglycoproteins / genetics. Soybean Proteins / therapeutic use

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GENISTEIN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867270.001).
  • [ISSN] 0022-3166
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 84926
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Sialoglycoproteins; 0 / Soybean Proteins; 0 / Spp1 protein, mouse; 106441-73-0 / Osteopontin; DH2M523P0H / Genistein
  •  go-up   go-down


67. El-Gohary YM, Silverman JF, Olson PR, Liu YL, Cohen JK, Miller R, Saad RS: Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol; 2007 Apr;127(4):572-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma.
  • We studied endoglin and vascular endothelial growth factor (VEGF) expression as prognostic markers in prostatic adenocarcinoma in 50 radical prostatectomy specimens.
  • Endoglin correlated positively with Gleason score, lymph node metastases, tumor stage, and preoperative prostate-specific antigen level (P < .05) but not with CD31.
  • Endoglin is a more specific and sensitive marker for tumor angiogenesis than CD31 and may serve as a prognostic marker for prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, CD / metabolism. Biomarkers, Tumor / analysis. Prostatic Neoplasms / metabolism. Receptors, Cell Surface / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17369132.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Receptors, Cell Surface; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


68. Suzue K, Montag AG, Tretiakova M, Yang XJ, Sahoo S: Altered expression of alpha-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy. Am J Clin Pathol; 2005 Apr;123(4):553-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of alpha-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy.
  • alpha-Methylacyl-coenzyme A racemase (AMACR) is a sensitive and specific tissue marker for the diagnosis of prostatic carcinoma.
  • However, limited data are available on AMACR expression in residual prostatic carcinoma following hormone therapy.
  • We analyzed 64 residual or recurrent prostatic adenocarcinomas following hormonal therapy for the expression of AMACR using a monoclonal antibody (P504S) to AMACR.
  • AMACR expression was reduced significantly in the majority of posthormonal residual carcinomas, whereas in postradiotherapy and in hormone-refractory metastatic prostatic adenocarcinoma, AMACR expression was retained.
  • Therefore, the diagnosis of residual prostatic carcinoma after hormonal therapy using AMACR immunostaining must be interpreted with caution.
  • Furthermore, AMACR might have a role in the recurrence of prostatic adenocarcinoma after medical therapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / therapy. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / therapy. Racemases and Epimerases / biosynthesis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15743746.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


69. Blah M, Gobet F, Dugardin F, Catovic B, Loisel F, Pfister C: [Elevation of total PSA after intravesical BCG instillations: granulomatous prostatitis or prostatic adenocarcinoma?]. Prog Urol; 2008 Feb;18(2):108-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Elevation of total PSA after intravesical BCG instillations: granulomatous prostatitis or prostatic adenocarcinoma?].
  • [Transliterated title] Elévation du PSA total après instillations endovesicales de BCG: prostatite granulomateuse ou adénocarcinome prostatique?
  • OBJECTIVE: The objective of this study was to evaluate the incidence of prostatic carcinoma in patients treated by intravesical BCG-therapy for superficial bladder cancer and presenting granulomatous prostatitis.
  • The authors discuss the problems of interpretation of total PSA and the potential indications for prostatic biopsies in this population.
  • A total of 153 men were treated for high-risk or intermediate-risk superficial bladder cancer according to the usual recommendations.
  • Ultrasound-guided biopsies were indicated in view of the persistently elevated PSA level and confirmed the tuberculoid granulomatous lesion of the prostate in each case and revealed prostatic adenocarcinoma in two patients.
  • CONCLUSION: Prostatic carcinoma must be systematically excluded by ultrasound-guided biopsies in all patients with clinical granulomatous prostatitis and persistently elevated PSA three months after intravesical BCG instillations.
  • [MeSH-major] Adenoma / diagnosis. BCG Vaccine / administration & dosage. Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis. Prostatitis / diagnosis. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Diagnosis, Differential. Drug Administration Schedule. Humans. Male. Retrospective Studies


70. Wang WH, Tsuji H, Ishikawa H, Tsujii H, Kamada T, Mizoe J, Li YX: [Comparison of treatment planning by carbon ion radiotherapy and by intensity-modulated radiotherapy for prostatic adenocarcinoma]. Zhonghua Zhong Liu Za Zhi; 2006 Nov;28(11):836-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of treatment planning by carbon ion radiotherapy and by intensity-modulated radiotherapy for prostatic adenocarcinoma].
  • OBJECTIVE: To evaluate the potential benefit of carbon ion radiotherapy (C-ion RT) through comparison with photon intensity-modulated radiotherapy (IMRT) in dose distribution for prostatic adenocarcinoma.
  • CONCLUSION: Compared with IMRT, C-ion RT can obtain better dose distribution, and may reduce tumor recurrence and radiation-induced complications in prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carbon Radioisotopes / therapeutic use. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416005.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carbon Radioisotopes
  •  go-up   go-down


71. Quick CM, Gokden N, Sangoi AR, Brooks JD, McKenney JK: The distribution of PAX-2 immunoreactivity in the prostate gland, seminal vesicle, and ejaculatory duct: comparison with prostatic adenocarcinoma and discussion of prostatic zonal embryogenesis. Hum Pathol; 2010 Aug;41(8):1145-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The distribution of PAX-2 immunoreactivity in the prostate gland, seminal vesicle, and ejaculatory duct: comparison with prostatic adenocarcinoma and discussion of prostatic zonal embryogenesis.
  • We studied PAX-2 expression in epithelium of normal seminal vesicle, normal ejaculatory duct, normal prostatic secretory epithelium, and prostatic adenocarcinoma to define its immunoreactivity pattern throughout the prostate gland and to evaluate its potential diagnostic role in the discrimination of seminal vesicle/ejaculatory duct epithelium from prostatic adenocarcinoma.
  • In addition, given that PAX-2 is highly expressed in tissues of wolffian duct embryologic origin, we also sought to confirm the divergent embryogenesis of the central zone, seminal vesicle, and ejaculatory duct from other regions of the prostate.
  • Prostatectomy specimens from 12 patients were reviewed to identify blocks containing seminal vesicle, ejaculatory duct, periurethral glands, benign prostatic glands, and prostatic acinar adenocarcinoma.
  • In addition, 2 tissue microarrays representing 15 additional seminal vesicles and 45 prostatic adenocarcinomas, 7 whole sections from prostatic adenocarcinomas of the central zone, and 5 core needle biopsies of seminal vesicle were also evaluated with anti-PAX-2 antibody.
  • In the 12 radical prostatectomy whole sections, nuclear reactivity for PAX-2 was identified in 12 (100%) of 12 of the seminal vesicle epithelium, 9 (90%) of 10 of the ejaculatory duct epithelium, 0 of 12 of the prostatic adenocarcinoma, and 0 of 6 of the high-grade prostatic intraepithelial neoplasia.
  • All 20 total additional seminal vesicles were positive for PAX-2 in the tissue microarray and biopsies; and all 52 additional prostatic adenocarcinomas were negative, including 7 of central zone origin.
  • Of the 19 total cases with evaluable central zone glands, 2 (10.5%) had focal nuclear reactivity in normal, benign prostatic secretory cells.
  • All other benign prostatic secretory epithelia from the peripheral and transition zones were negative for PAX-2.
  • No reactivity for PAX-2 was seen in prostatic adenocarcinoma or high-grade prostatic intraepithelial neoplasia.
  • In addition, these data add further support to the proposed embryogenesis of the prostatic central zone, seminal vesicle, and ejaculatory ducts from the wolffian system.
  • [MeSH-major] Adenocarcinoma / metabolism. Ejaculatory Ducts / pathology. PAX2 Transcription Factor / metabolism. Prostate / embryology. Prostatic Neoplasms / metabolism. Seminal Vesicles / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20413145.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human
  •  go-up   go-down


72. Rabien A, Fritzsche F, Jung M, Diamandis EP, Loening SA, Dietel M, Jung K, Stephan C, Kristiansen G: High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse. Tumour Biol; 2008;29(1):1-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse.
  • OBJECTIVE: Reliable prognostic tools for prostate cancer are still needed and KLK14, a young member of the growing family of human kallikrein-related peptidases, has been estimated to become a new significant marker.
  • It is the aim of this study to analyze the clinical value of immunohistochemical expression of KLK14 in prostate cancer tissue samples.
  • Areas of normal prostatic tissue, of prostatic epithelial neoplasia and of prostatic adenocarcinoma were checked in relation to clinicopathological parameters of the patients.
  • Expression of KLK14 mRNA was quantified in 25 matches of normal and cancerous prostatic tissue, collected by laser capture microdissection.
  • RESULTS: Expression of the KLK14 protein correlated with the pathological tumor status in prostate cancer and was associated with disease progression defined by prostate-specific antigen relapse in univariate Kaplan-Meier analysis.
  • The multivariate Cox proportional hazards regression model proved KLK14 to be an independent prognostic factor in prostate cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Kallikreins / genetics. Prostate-Specific Antigen / blood. Prostatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18497543.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 3.4.21.- / KLK14 protein, human; EC 3.4.21.- / Kallikreins; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


73. Doyle S, Rodriguez C, Madabhushi A, Tomaszeweski J, Feldman M: Detecting prostatic adenocarcinoma from digitized histology using a multi-scale hierarchical classification approach. Conf Proc IEEE Eng Med Biol Soc; 2006;1:4759-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detecting prostatic adenocarcinoma from digitized histology using a multi-scale hierarchical classification approach.
  • In this paper we present a computer-aided diagnosis (CAD) system to automatically detect prostatic adenocarcinoma from high resolution digital histopathological slides.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Diagnosis, Computer-Assisted / instrumentation. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17947116.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


74. Park PC, Mai KT, Roustan Delatour NL, Morash C, Cagiannos I: Predictive value of prostatic adenocarcinoma after a negative prostate biopsy. BJU Int; 2006 Nov;98(5):986-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of prostatic adenocarcinoma after a negative prostate biopsy.
  • OBJECTIVE: To investigate the predictive value (PV) for all prostate cancers and for clinically significant cancer undiagnosed after a 10-core biopsy protocol, as the 10-core transrectal ultrasonography-guided biopsy is considered the standard technique of prostatic biopsy due to its high rate of detection of prostatic adenocarcinoma.
  • Cases with unilateral core involvement by prostate cancer were retained for study.
  • RESULTS: In all, 70 resected prostates (RP) had unilateral core involvement by prostate cancer.
  • In 38 cases, there was cancer in the biopsy-negative hemi-prostates (group 1); in the remaining 32 the hemi-prostates were free of cancer (group 2).
  • Specifically, 23 cases had one to eight foci of prostate cancer in the posterior nontransitional zone (NTZ) (group 1a), while 15 had two to six foci of prostate cancer in the transitional zone (TZ), or the anterior horn (AH) of the peripheral zone or the TZ and AH (group 1b).
  • There were two cases with clinically significant prostate cancer in group 1a, and six in group 1b.
  • CONCLUSIONS: The PV of a negative five-core biopsy protocol on a hemi-prostate is 54% for prostate cancer and 11% for clinically significant prostate cancer.
  • Most clinically significant prostate cancers were in the AH/TZ of the prostate.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Needle / methods. Humans. Male. Middle Aged. Predictive Value of Tests. Prostate-Specific Antigen / blood. Prostatectomy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17034600.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


75. Memon A, Ahmad Z, Qureshi A, Ahsan A, Barakzai A, Bhurgri Y: Staging of prostatic adenocarcinoma with radical prostatectomy specimens in Pakistan. Asian Pac J Cancer Prev; 2009 Oct-Dec;10(4):551-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging of prostatic adenocarcinoma with radical prostatectomy specimens in Pakistan.
  • Therefore, in the majority of cases, disease was not localized to the prostate and perineurial invasion was seen in all.
  • CONCLUSIONS: The large majority of prostatic carcinomas in Pakistan are advanced cancers with pathologic stage more advanced than evident on clinical staging.
  • On average, tumors involved 35-40% of the prostate with a particular preponderance in posterior lobes.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatectomy. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827867.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


76. Samaratunga H, Samaratunga D, Perry-Keene J, Adamson M, Yaxley J, Delahunt B: Distal seminal vesicle invasion by prostate adenocarcinoma does not occur in isolation of proximal seminal vesicle invasion or lymphovascular infiltration. Pathology; 2010 Jun;42(4):330-3
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distal seminal vesicle invasion by prostate adenocarcinoma does not occur in isolation of proximal seminal vesicle invasion or lymphovascular infiltration.
  • AIMS: Seminal vesicle (SV) invasion by prostatic adenocarcinoma is a poor prognostic indicator.
  • This study examines the distribution of invasive prostatic adenocarcinoma in SVs and makes recommendations regarding sampling procedures.
  • The site of invasive prostatic carcinoma within the muscular wall of the SV and its presence in the ejaculatory duct was recorded.
  • Patients ranged in age from 52 to 73 years (mean 64 years), with a serum prostatic specific antigen ranging from 3.7 to 46 ng/mL (mean 10.6 ng/mL).
  • All but one of the SV positive cases (98.2%) had involvement of the proximal third (15 right, 17 left and 23 both) of the gland, 35 of which (63.6%) had infiltration only of the proximal SV.
  • Lymphovascular invasion within the prostate was seen in 71.4% of cases.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology. Seminal Vesicles / pathology
  • [MeSH-minor] Aged. Digital Rectal Examination. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Prognosis. Prostate-Specific Antigen / blood. Prostatectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20438404.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


77. Herawi M, Parwani AV, Irie J, Epstein JI: Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion. Am J Surg Pathol; 2005 Jul;29(7):874-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion.
  • The current study aimed to determine the incidence of various benign mimickers of prostatic adenocarcinoma most commonly encountered in a busy consultation practice.
  • All prostate needle biopsies from the consult service of one of the authors were prospectively evaluated over a 7-month period.
  • Crowded benign glands, insufficiently crowded or numerous to warrant a diagnosis of adenosis, was the second most common mimicker (146 of 567; 25.7%).
  • In the past, complete atrophy, adenosis, seminal vesicle, and granulomatous prostatitis were considered common mimickers of prostate cancer on prostatic needle biopsies.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Atrophy / metabolism. Atrophy / pathology. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. Referral and Consultation

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958851.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


78. Cortés González JR, Garza R, Martínez R, Gómez L: [Prostate adenocarcinoma metastatic to penis]. Actas Urol Esp; 2006 Sep;30(8):832-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostate adenocarcinoma metastatic to penis].
  • [Transliterated title] Adenocarcinoma de próstata metastático a pene.
  • Prostate cancer is a disease that appears with a very high frequency.
  • We present one case of a patient with painless metastatic nodules on the penis secondary to a prostate cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Penile Neoplasms / secondary. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Actas Urol Esp. 2006 Oct;30(9):962-4 [17175940.001]
  • (PMID = 17078582.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 6
  •  go-up   go-down


79. Aydin H, Zhou M, Herawi M, Epstein JI: Number and location of nucleoli and presence of apoptotic bodies in diagnostically challenging cases of prostate adenocarcinoma on needle biopsy. Hum Pathol; 2005 Nov;36(11):1172-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Number and location of nucleoli and presence of apoptotic bodies in diagnostically challenging cases of prostate adenocarcinoma on needle biopsy.
  • There is limited published data regarding the significance of the number or position of nucleoli and the presence of apoptotic bodies in diagnostically challenging cases of adenocarcinoma of the prostate on needle biopsy material.
  • One hundred consecutive prostate cancers on needle biopsy were sent because of diagnostic difficulty to an expert in urological pathology, and the remaining normal benign prostatic glands on the same core were evaluated for the number and location of nucleoli and for the presence of mitotic figures and apoptotic bodies.
  • For comparison, the same parameters were evaluated in mimickers of cancer on needle biopsy from other cases, including partial atrophy (n = 135), fully developed atrophy (n = 89), adenosis (n = 50), prostate glands with acute inflammation (n = 50), and high-grade prostatic intraepithelial neoplasia (n = 100).
  • Although the number and position of nucleoli did not discriminate between cancer and benign mimickers, mitotic figures and apoptotic bodies were more commonly seen in cancer.
  • Apoptotic bodies in particular were seen fairly frequently (34%) in prostatic adenocarcinoma (also seen in 13% of high-grade prostatic intraepithelial neoplasia), yet rarely in benign mimickers on needle biopsy.
  • Our findings indicate that the presence of apoptotic bodies should be added to the list of histological features that are helpful in the diagnosis of challenging cases of prostate cancer on needle biopsy.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Cell Nucleolus / pathology. Inclusion Bodies / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Apoptosis / physiology. Biopsy, Needle. Humans. Immunohistochemistry. Male. Prostatic Diseases / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16260270.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


80. Castro Gómez JE, Anido Herranz U, Carballo Castro A, Gómez Caamaóo A, León Mateos LA, Porto Vázquez C, López López R: Brain metastases from prostate adenocarcinoma. Clin Transl Oncol; 2009 Jan;11(1):63-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases from prostate adenocarcinoma.
  • Brain metastases of prostate adenocarcinoma are rare.
  • We report a case of brain metastases from prostate adenocarcinoma 15 months after the diagnosis of the primary tumour.
  • The biopsy performed showed metastatic prostate adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155207.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


81. Cheng YK, Wang TC, Yang JT, Lee MH, Su CH: Dural metastasis from prostatic adenocarcinoma mimicking chronic subdural hematoma. J Clin Neurosci; 2009 Aug;16(8):1084-6
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dural metastasis from prostatic adenocarcinoma mimicking chronic subdural hematoma.
  • Histopathology revealed metastatic prostatic carcinoma.
  • As the surgical approach and prognosis of chronic subdural hematoma and metastatic tumors are completely different, the differential diagnosis of these diseases is very important.
  • [MeSH-major] Adenocarcinoma / secondary. Dura Mater. Hematoma, Subdural, Chronic / diagnosis. Meningeal Neoplasms / secondary. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Brain / pathology. Brain / radiography. Brain / surgery. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19427220.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


82. Patel V, Castell FA, Akinwunmi J, Francis I, Chandrasekharan L, Malhotra R: Prostatic adenocarcinoma presenting with metastatic frontal bone involvement and orbital invasion. Orbit; 2010 Aug;29(4):213-5
MedlinePlus Health Information. consumer health - Prostate Cancer Screening.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic adenocarcinoma presenting with metastatic frontal bone involvement and orbital invasion.
  • We present a rare case of prostatic adenocarcinoma presenting with metastatic frontal bone involvement with subsequent spread to the orbit.
  • Although prostatic adenocarcinoma has a strong tendency to metastasize to bone, particularly axial skeletal bone, frontal bone involvement is rare and subsequent orbital involvement is even more so.
  • [MeSH-major] Adenocarcinoma / secondary. Neoplasm Invasiveness / pathology. Orbital Neoplasms / secondary. Orbital Neoplasms / surgery. Prostate-Specific Antigen / blood. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents, Hormonal / therapeutic use. Biopsy, Needle. Diagnosis, Differential. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Neoplasm Staging. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20812840.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


83. Chua CW, Chiu YT, Yuen HF, Chan KW, Wang X, Ling MT, Wong YC: Differential expression of MSX2 in nodular hyperplasia, high-grade prostatic intraepithelial neoplasia and prostate adenocarcinoma. APMIS; 2010 Dec;118(12):918-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of MSX2 in nodular hyperplasia, high-grade prostatic intraepithelial neoplasia and prostate adenocarcinoma.
  • One of the common features in advanced prostate cancer is bone metastasis.
  • In this study, we investigated the clinical relevance of a bone factor, MSX2, in predicting the metastatic ability of prostate adenocarcinoma.
  • Evaluation of MSX2 expression was performed using prostate cell lines as well as patient specimens.
  • A sharp decrease in MSX2 was found in primary prostate cancer cells, 22Rv1, when compared with the non-malignant counterparts, followed by a gradual increase in more aggressive prostate cancer cell lines.
  • Interestingly, the MSX2 protein was upregulated and predominantly expressed in the nucleus in aggressive prostate cancer cell line, C4-2b, compared with the less aggressive 22Rv1.
  • Consistent with the in vitro results, MSX2 nuclear expression was significantly higher in nodular hyperplasia when compared with high-grade prostatic intraepithelial neoplasia (PIN), while MSX2 nuclear expression in prostate adenocarcinoma was higher than that in high-grade PIN.
  • Taken together, MSX2 may serve as a potential biomarker in predicting primary prostate tumors with higher metastatic capability.
  • [MeSH-major] Adenocarcinoma / metabolism. Homeodomain Proteins / biosynthesis. Prostatic Hyperplasia / metabolism. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal Compilation © 2010 APMIS.
  • (PMID = 21091772.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / MSX2 protein
  •  go-up   go-down


84. Mourra N, Parc Y, McNamara D, Tiret E, Flejou JF, Parc R: Lymph node metastases of prostatic adenocarcinoma in the mesorectum in patients with adenocarcinoma or villous tumor of the rectum with collision phenomenon in a single lymph node: report of five cases. Dis Colon Rectum; 2005 Feb;48(2):384-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node metastases of prostatic adenocarcinoma in the mesorectum in patients with adenocarcinoma or villous tumor of the rectum with collision phenomenon in a single lymph node: report of five cases.
  • PURPOSE: Lymph node involvement is the most important prognostic factor when staging patients with rectal cancer.
  • Cancer originating from sites other than rectum rarely may metastasize to the mesorectum.
  • We report five patients with metastatic prostatic carcinoma to mesorectal lymph nodes, with the "collision phenomenon" in one lymph node.
  • The diagnosis of prostate cancer was clinically unsuspected in two cases.
  • METHODS: We examined three cases of primary adenocarcinoma and two villous tumors with high-grade dysplasia (patient age range, 52-74 (mean, 63) years) of the middle or lower third of the rectum.
  • RESULTS: Of 106 lymph nodes examined, 20 contained metastases: 9 from rectal adenocarcinoma, 10 from prostatic adenocarcinoma, and 1 with metastatic foci from both tumors.
  • The diagnosis of prostatic carcinoma was readily confirmed by immunostaining for prostatic-specific antigen, and prostatic acid phosphatase.
  • CONCLUSIONS: Mesorectal lymph node dissection provides prognostic information in rectal cancer, but careful examination may reveal other unsuspected pathology.
  • [MeSH-major] Adenocarcinoma / secondary. Prostatic Neoplasms / pathology. Rectal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15812588.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Baydar DE, Ozen H, Geyik PO, Gurel B: Can telomere alterations predict biochemical recurrence in prostate adenocarcinoma? A preliminary study. Pathol Res Pract; 2010 Oct 15;206(10):700-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can telomere alterations predict biochemical recurrence in prostate adenocarcinoma? A preliminary study.
  • Telomere shortening can be one of the ways that cause chromosomal instability in the pathogenesis of prostatic carcinoma.
  • In the current study, we evaluated telomere length (TL) in normal and malignant prostate tissues, and its association with prognostic factors and with time to biochemical tumor recurrence.
  • The majority (49/61) of prostate cancers displayed abnormally short telomeres.
  • Telomere shortening is a common alteration in prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Prostatic Neoplasms / genetics. Telomere / metabolism
  • [MeSH-minor] Aged. Disease-Free Survival. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Logistic Models. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pilot Projects. Proportional Hazards Models. Prostate-Specific Antigen / blood. Prostatectomy. Risk Assessment. Risk Factors. Time Factors. Tissue Array Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20674190.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


86. Nassif AE, Tâmbara Filho R, Paula RX, Taguchi WS, Pozzobon HJ: [Epidemiologic profile and prognostic factors in clinically localized prostate adenocarcinoma submitted to surgical treatment]. Rev Col Bras Cir; 2009 Aug;36(4):327-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiologic profile and prognostic factors in clinically localized prostate adenocarcinoma submitted to surgical treatment].
  • [Transliterated title] Perfil epidemiológico e fatores prognósticos no tratamento cirúrgico do adenocarcinoma de próstata clinicamente localizado.
  • OBJECTIVE: Radical prostatectomy remains the standard treatment for early prostate cancer.
  • METHODS: A total of 500 patients with prostate cancer underwent radical prostatectomy at Santa Rita hospital- Maringa-PR, between 2000 and 2006.
  • Clinical staging, preoperative prostate-specific antigen (PSA) and Gleason score were evaluated with pathological stage and margin status.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / surgery. Prostatectomy. Prostatic Neoplasms / epidemiology. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20076923.001).
  • [ISSN] 1809-4546
  • [Journal-full-title] Revista do Colégio Brasileiro de Cirurgiões
  • [ISO-abbreviation] Rev Col Bras Cir
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  •  go-up   go-down


87. Harik L, Nassar A: Extranodal Rosai-Dorfman disease of the kidney and coexistent poorly differentiated prostatic adenocarcinoma. Arch Pathol Lab Med; 2006 Aug;130(8):1223-6
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal Rosai-Dorfman disease of the kidney and coexistent poorly differentiated prostatic adenocarcinoma.
  • We present a case of a patient who was initially diagnosed with poorly differentiated prostatic adenocarcinoma on prostate needle core biopsy.
  • Lymphadenectomy revealed metastatic prostatic adenocarcinoma; however, the lymph nodes did not show evidence of Rosai-Dorfman disease.
  • The combination of prostatic adenocarcinoma and isolated extranodal Rosai-Dorfman disease of the kidney makes this case unique.
  • [MeSH-major] Adenocarcinoma / complications. Histiocytosis, Sinus / complications. Kidney Diseases / complications. Prostatic Neoplasms / complications

  • Genetic Alliance. consumer health - Kidney Disease.
  • Genetic Alliance. consumer health - Rosai-Dorfman disease.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879029.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Biomarkers, Tumor
  •  go-up   go-down


88. Yamashita R, Matsuzaki M, Matsui T, Yamaguchi R, Yuen K, Niwakawa M, Tobisu K: [Clinical characteristics of prostatic adenocarcinoma with ductal features]. Nihon Hinyokika Gakkai Zasshi; 2008 Mar;99(3):525-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics of prostatic adenocarcinoma with ductal features].
  • PURPOSE: To determine the incidence and prognosis of prostatic ductal adenocarcinoma.
  • We differentiated prostatic cases of ductal adenocarcinoma that were larger than 5 mm in diameter from cases of acinar adenocarcinomas.
  • We then examined these two groups for the pathological stages of the neoplasms and the incidence of postoperative prostate-specific antigen (PSA) failure.
  • RESULTS: We found eight cases (12%) of prostatic ductal adenocarcinoma among the 64 cases treated with radical prostatectomies.
  • In addition, one case was identified as pure ductal adenocarcinoma.
  • During the follow-up period, four of the eight cases of ductal adenocarcinoma (50%) and twelve of the 56 cases of acinar adenocarcinoma (21%) showed postoperative PSA failure.
  • CONCLUSIONS: We identified eight cases of ducal adenocarcinoma (12% of the examined cases), which suggests this disease is not as rare as previously reported.
  • Compared to the cases of acinar adenocarcinoma, the cases of ductal adenocarcinoma were at a more advanced pathological stage and resulted in a higher rate of postoperative PSA failure.
  • Therefore, we believe that patients that show even a limited degree of ductal adenocarcinoma should receive aggressive therapy.
  • [MeSH-major] Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / therapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / therapy. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Neoplasms, Multiple Primary. Prognosis. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404881.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


89. Chang F, Dávila S, Ovalles V, Mejías E, Rodríguez O, Rodríguez R: [Cervical adenopathy presentation of adenocarcinoma of prostate]. Actas Urol Esp; 2007 Nov-Dec;31(10):1193-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cervical adenopathy presentation of adenocarcinoma of prostate].
  • [Transliterated title] Adenopatía cervical como presentación de adenocarcinoma de próstata.
  • The metastases of prostate cancer shows the regional lymphatic dissemination, being the cervical lymphatic metastases to infrequent and little reported in Literature.
  • When making biopsy of cervical adenopathy reported adenocarcinoma prostate metastases.
  • Within the diagnosis differential of the cervical adenopathys in neck in adult men it must consider the prostate carcinoma, because in an early diagnosis and adapting treatment it can prolong the survive.
  • [MeSH-major] Adenocarcinoma / secondary. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18314662.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


90. Dalfior D, Delahunt B, Brunelli M, Parisi A, Ficarra V, Novara G, Novella G, Gobbo S, Valotto C, Chilosi M, Menestrina F, Martignoni G: Utility of racemase and other immunomarkers in the detection of adenocarcinoma in prostatic tissue damaged by high intensity focused ultrasound therapy. Pathology; 2010 Jan;42(1):1-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of racemase and other immunomarkers in the detection of adenocarcinoma in prostatic tissue damaged by high intensity focused ultrasound therapy.
  • AIMS: High intensity focused ultrasound (HIFU) is an emerging alternative for the treatment of prostate adenocarcinoma.
  • Alpha-methylacyl-CoA racemase (AMACR) has been shown to be a sensitive immunomarker for prostate cancer, however, there is no information available concerning its utility and that of other immunomarkers for the detection of malignancy after HIFU therapy.
  • METHODS: AMACR expression was examined in 11 cases of prostatic carcinoma treated by HIFU, with histological evidence of residual carcinoma.
  • In seven cases tumour was examined from thin core biopsies and in four cases from tissue fragments obtained by transurethral resection of prostate (TURP).
  • In addition to AMACR, immunostaining was also undertaken for p63, cytokeratin 34betaE12, cytokeratin 5, cytokeratin 8-18, prostate specific alkaline phosphatase (PSAP), prostate specific antigen (PSA), chromogranin and CD56.
  • Cytokeratin 34betaE12, cytokeratin 5, and p63 marked the basal layer in normal prostatic glands, but were negative in neoplastic glands.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenocarcinoma / therapy. Biomarkers, Tumor / metabolism. Prostatic Neoplasms / enzymology. Prostatic Neoplasms / therapy. Racemases and Epimerases / metabolism. Ultrasonic Therapy / methods
  • [MeSH-minor] Ablation Techniques / methods. Combined Modality Therapy. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Keratin-5 / metabolism. Keratins / metabolism. Male. Necrosis / pathology. Necrosis / ultrasonography. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20025473.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CK-34 beta E12; 0 / Keratin-5; 68238-35-7 / Keratins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


91. Khan R, Maheshwari V, Harris SH, Alam K: Prostatic adenocarcinoma metastasizing to the parietal bones. Indian J Pathol Microbiol; 2007 Oct;50(4):759-61
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic adenocarcinoma metastasizing to the parietal bones.
  • Prostate cancer metastasis to the axial skeleton occurs at high frequency in patients with advanced disease causing significant morbidity and mortality.
  • Parietal bone metastasis from prostatic adenocarcinoma was the initial presentation seen in our patient.
  • This is the first case of its kind in the literature where the prostatic carcinoma had metastasized to the parietal bones of the skull without any symptomatology of prostatic involvement.
  • The report is intended to alert the reader of this rare site of metastasis from the prostate.
  • [MeSH-major] Adenocarcinoma / secondary. Parietal Bone / pathology. Prostatic Neoplasms / pathology. Skull Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306543.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


92. Nese N, Kandiloglu AR, Simsek G, Lekili M, Ozdamar A, Catalkaya A, Coskun T: Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin. Anal Quant Cytol Histol; 2010 Apr;32(2):90-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin.
  • OBJECTIVE: To investigate the diversity within invasive ductal carcinoma (IDC) and prostatic adenocarcinoma (PCa) by evaluating immunohistochemical expression of heat shock protein 47 (HSP47) and fascin, the molecules that are related to desmoplasia and invasion, and analyze its correlation with clinicopathologic parameters.

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701077.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / FSCN1 protein, human; 0 / HSP47 Heat-Shock Proteins; 0 / Microfilament Proteins
  •  go-up   go-down


93. Lath CO, Khanna PC, Gadewar S, Patkar DP: Intracranial metastasis from prostatic adenocarcinoma simulating a meningioma. Australas Radiol; 2005 Dec;49(6):497-500
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial metastasis from prostatic adenocarcinoma simulating a meningioma.
  • We report an unusual case of extra-axial metastatic adenocarcinoma of the prostate that closely simulated a frontal, parasagittal, dural-based meningioma.
  • Such tumours, which satisfy several criteria for a diagnosis of meningioma, but which have proved instead to be metastatic adenocarcinoma of the prostate, form the focus of our report.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Prostatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Meningioma / radiography. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351616.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


94. Doganavsargil B, Simsir A, Boyacioglu H, Cal C, Hekimgil M: A comparison of p21 and p27 immunoexpression in benign glands, prostatic intraepithelial neoplasia and prostate adenocarcinoma. BJU Int; 2006 Mar;97(3):644-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of p21 and p27 immunoexpression in benign glands, prostatic intraepithelial neoplasia and prostate adenocarcinoma.
  • OBJECTIVE: To assess the immunoexpression of p21 and p27 proteins in consecutive areas of benign glands, prostatic intraepithelial neoplasia (PIN) and prostate adenocarcinoma.
  • PATIENTS AND METHODS: Tissue from 91 patients who had a radical prostatectomy was assessed by immunohistochemistry to evaluate the expression of p21 and p27 in adjacent areas of benign glands, PIN and prostate adenocarcinoma.
  • The results were correlated with various clinicopathological variables, e.g. age, total prostate-specific antigen level, tumour stage, Gleason score, surgical margin involvement, extraprostatic extension, seminal vesicle invasion, and perineural invasion.
  • The decline in p27 with advancing age in tumour and PIN areas may be a possible explanation of the greater frequency of prostate adenocarcinoma in older men.
  • [MeSH-major] Adenocarcinoma / chemistry. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Cyclin-Dependent Kinase Inhibitor p27 / analysis. Neoplasm Proteins / analysis. Prostatic Intraepithelial Neoplasia / chemistry. Prostatic Neoplasms / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16469041.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Neoplasm Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


95. Maĭborodin IV, Back Ch: [Macrophageal antigen in the prostatic adenocarcinoma cells]. Arkh Patol; 2006 May-Jun;68(3):30-1
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Macrophageal antigen in the prostatic adenocarcinoma cells].
  • [MeSH-major] Adenocarcinoma / immunology. Antigens / analysis. Macrophages / immunology. Prostatic Neoplasms / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16830622.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens
  •  go-up   go-down


96. Bai AS, Zeng H, Li X, Wei Q, Li H, Yang YR: [Expression of kinase insert domain-containing receptor in prostate adenocarcinoma]. Zhonghua Nan Ke Xue; 2007 Apr;13(4):324-6
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of kinase insert domain-containing receptor in prostate adenocarcinoma].
  • OBJECTIVE: To investigate the correlation between the expression of the kinase insert domain-containing receptor (KDR) and the histological grade of prostate adenocarcinoma.
  • METHODS: Forty-eight samples of prostate adenocarcinoma tissues and 20 samples of benign prostatic hypertrophy (BPH) tissues were studied by LsAB immunohistochemical staining.
  • RESULTS: The positive expression rate of KDR was 73% in prostate adenocarcinoma and 30% in BPH.
  • The expression of KDR was stronger in prostate adenocarcinoma, and there was no relationship between staining intensity and the histological grade of carcinoma.
  • CONCLUSION: KDR, expressed more highly in prostate adenocarcinoma, promises to be a new target in the treatment of prostate adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / metabolism. Receptors, Vascular Endothelial Growth Factor / biosynthesis. Vascular Endothelial Growth Factor Receptor-2 / biosynthesis

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17491265.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


97. Taverna G, Colombo P, Seveso M, Giusti G, Piccinelli A, Benetti A, Graziotti P: Single small focus of prostate adenocarcinoma (&lt; or = 1 mm and too small for grading) and clinical significant disease after radical prostatectomy. Arch Ital Urol Androl; 2006 Jun;78(2):57-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single small focus of prostate adenocarcinoma (< or = 1 mm and too small for grading) and clinical significant disease after radical prostatectomy.
  • OBJECTIVES: To determine whether a clinical significant adenocarcinoma of the cinoma (defined as a lesion < or =1 mm. and too small for grading) at needle biopsy, even repeated, and through prostate specific antigen (PSA), PSA density (PSAD) and free-to-total PSA ratio (f/t ratio).
  • METHODS: Retrospectively 79/1610 consecutive patients undergoing prostatic needle biopsies presented one small focus of prostatic adenocarcinoma < or =1 mm and too small for grading.
  • All patients were submitted to radical retropubic prostatectomy (RRP) and were divided into three groups: group A (28/79 patients, 35.4%) submitted to RRP after diagnosis of just one small focus of adenocarcinoma at first biopsy; group B (26/79 patients, 32.9%) submitted to RRP after two successive diagnoses of small focus of adenocarcinoma; group C (25/79 patients, 31.6%) submitted to RRP after diagnosis of adenocarcinoma larger than 1 mm at successive biopsy in which Gleason score had been applied.
  • The aim of this retrospective study is to analyze the correlation between a single small focus of adenocarcinoma by prostatic biopsy, even repeated, and the clinical significant disease on the following radical retropubic prostatectomy.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929604.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


98. Gidwani A, Gidwani S, Khan A, Carson J: Concurrent malakoplakia of cervical lymph nodes and prostatic adenocarcinoma with bony metastasis: case report. Ghana Med J; 2006;40(4):151-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent malakoplakia of cervical lymph nodes and prostatic adenocarcinoma with bony metastasis: case report.
  • SummaryAn unusual case of malakoplakia of the cervical lymph nodes in a patient with bony metastasis from prostrate cancer is reported.
  • An 80-year-old patient with metastatic prostatic cancer presented with bilateral cervical lymphadenopathy, and a hard cervical mass in the left supraclavicular region.
  • Biopsy of the lymph gland revealed the presence of malakoplakia, with no evidence of metastatic prostatic carcinoma.
  • Though co-existence of malakoplakia and adenocarcinoma within the prostrate gland has been reported before, this case is unique, as it highlights the rare occurrence of malakoplakia involving distant nodes in a patient with bony metastatic prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1240-2 [14623758.001]
  • [Cites] Pathol Oncol Res. 2002;8(3):202-3 [12516002.001]
  • [Cites] Br J Urol. 1982 Apr;54(2):181-5 [7082937.001]
  • [Cites] Urol Int. 1998 Oct;61(1):47-9 [9792984.001]
  • (PMID = 17496990.001).
  • [ISSN] 0016-9560
  • [Journal-full-title] Ghana medical journal
  • [ISO-abbreviation] Ghana Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ghana
  • [Other-IDs] NLM/ PMC1868010
  •  go-up   go-down


99. Sung MT, Eble JN, Cheng L: Invasion of fat justifies assignment of stage pT3a in prostatic adenocarcinoma. Pathology; 2006 Aug;38(4):309-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasion of fat justifies assignment of stage pT3a in prostatic adenocarcinoma.
  • AIMS: The detection of invasive cancer cells within the adipose tissue of needle biopsies has been regarded as bona fide evidence of extraprostatic tumour extension, and as a consequence may influence subsequent patient management.
  • We examined totally embedded, whole-mounted radical prostatectomy specimens in order to determine the occurrence of intraprostatic fat in prostatic tissue, and further, to assess the importance of the identification of fat infiltration by neoplastic cells in needle biopsy specimens as a marker of extraprostatic infiltration by tumour.
  • METHODS: Between 2000 and 2003, 313 consecutive patients underwent radical prostatectomy for clinically localised prostate cancer in the Indiana University Hospital.
  • Other pathological characteristics of prostate cancer were also assessed and clinical data were gathered by a review of patient charts.
  • None of these 313 radical prostatectomy specimens revealed any adipose tissue components within the most peripheral boundary of normal prostatic acini in the prostate.
  • CONCLUSIONS: We found no evidence of intraprostatic fat and our findings suggest that, at best, the occurrence of fat within the prostate is of extreme rarity.
  • [MeSH-major] Adenocarcinoma / pathology. Adipose Tissue / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916718.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


100. Mai KT, Belanger EC, Al-Maghrabi HM, Robertson S, Wang D, Margnean C: Primary prostatic central zone adenocarcinoma. Pathol Res Pract; 2008;204(4):251-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary prostatic central zone adenocarcinoma.
  • The central zone (CZ) of the prostate is embryologically, anatomically, and histologically distinct.
  • High-grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma (PAC) are encountered in the CZ, but have not been well studied.
  • The correlating positive biopsy cores were from the mid portion or from base of prostate and contained foci of HGPIN in 4/7 cases.
  • Preoperative diagnosis of CZ PAC can be suspected due to the histopathological features in the biopsy and is important to improve the free surgical resection rate.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Ductal / pathology. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18178014.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement